Programme Ectrims 2017

Scientific Programme

Wednesday, 25 October 2017

Teaching Courses, Hall C08:30 - 10:00 Teaching Course 1: Disease modifying treatment

ChairsR.J. Fox (Cleveland, US)L. Kappos (Basel, CH)

08:30 - 09:00 DMTs 2017: new MS treatments and updates on established treatments R.J. Fox (Cleveland, US)

09:00 - 09:30 Defining what is working: choosing when and how to escalate therapy L. Kappos (Basel, CH)

09:30 - 10:00 Clinical trial statistics: pearls and lessons from MS trials M.P. Sormani (Genoa, IT)

Teaching Courses, Hall D08:30 - 10:00 Teaching Course 2: MS and reproduction: from

contraception to post conception reproductiveepidemiology and planning a pregnancy in women with MS

ChairsK. Hellwig (Bochum, DE)A.M. Langer-Gould (Pasadena, US)

08:30 - 09:00 Counselling of women with MS in the reproductive age – fromcontraception to conception-general recommendations

M.K. Houtchens (Brookline, US)

09:00 - 09:30 Multiple Sclerosis and pregnancy management in 2017: medications andlactation

K. Hellwig (Bochum, DE)

09:30 - 10:00 Reproductive epidemiology in multiple sclerosis (puberty, pregnancy,breastfeeding, assisted reproductive techniques and menopause)

A.M. Langer-Gould (Pasadena, US)

Teaching Courses, Hall E08:30 - 10:00 Teaching Course 5: Biomarkers in MS

ChairsB. Hemmer (Munich, DE)M. Comabella (Barcelona, ES)

/ 97


08:30 - 09:00 General considerations to develop and use biomarkers in MS B. Hemmer (Munich, DE)

09:00 - 09:30 Biomarkers of neuroinflammation M. Comabella (Barcelona, ES)

09:30 - 10:00 Biomarkers of CNS neurodegeneration M. Otto (Ulm, DE)

Teaching Courses, Hall F08:30 - 10:00 Teaching Course 4: Myelin repair: scientific background

and clinical implications

ChairsB. Stankoff (Paris, FR)L. Leocani (Milan, IT)

08:30 - 09:00 Mechanisms leading to success or failure of myelin repair in the centralnervous system

R. Franklin (Cambridge, GB)

09:00 - 09:30 Evaluation of myelin repair: electrophysiological outcomes L. Leocani (Milan, IT)

09:30 - 10:00 Evaluation of myelin repair: imaging outcomes B. Stankoff (Paris, FR)

Teaching Courses, Hall G08:30 - 10:00 Teaching Course 3: Advanced MS genetics and

immunology

ChairsR. Liblau (Toulouse, FR)F. Zipp (Mainz, DE)

08:30 - 09:00 The MS genomic map: translating genetic architecture into a roadmap fordissecting neuroimmune mechanisms

P. De Jager (New York, US)

09:00 - 09:30 Immunology of MS: how does the pathogenic adaptive immune responsedevelop?

R. Liblau (Toulouse, FR)

09:30 - 10:00 Immunology of MS: innate and adaptive immune events within the CNS F. Zipp (Mainz, DE)

/ 97


Teaching Courses, Hall C10:30 - 12:00 Teaching Course 6: Controversy in management

ChairsA.E. Miller (New York, US)X. Montalban (Barcelona, ES)

10:30 - 11:00 Case 1: relapsing MS A.E. Miller (New York, US)

11:00 - 11:30 Case 2: progressive MS X. Montalban (Barcelona, ES)

11:30 - 12:00 Case 3: Neuromyelitis optica spectrum disorder (NMOSD) I. Katz Sand (New York, US)

Teaching Courses, Hall D10:30 - 12:00 Teaching Course 7: Symptomatic therapy of gait

disturbances, spasticity, bladder dysfunction andparoxysmal symptoms

ChairsT. Berger (Innsbruck, AT)M. Pakzad (London, GB)

10:30 - 11:00 Bladder dysfunction: pitfalls and challenges M. Pakzad (London, GB)

11:00 - 11:30 Spasticity and walking impairment: early to recognize and to treat C. Oreja-Guevara (Madrid, ES)

11:30 - 12:00 Paroxysmal symptoms: often neglected, but treatment needed T. Berger (Innsbruck, AT)

Teaching Courses, Hall E10:30 - 12:00 Teaching Course 8: Brain atrophy in clinical practice:

evidence base and barriers to implementation

ChairsF. Barkhof (Amsterdam, NL)J. Sastre-Garriga (Barcelona, ES)

10:30 - 11:00 Natural history & clinical relevance of brain volume changes in patientswith MS

F. Barkhof (Amsterdam, NL)

11:00 - 11:30 Value of brain volume changes to predict treatment response in patientswith MS

J. Sastre-Garriga (Barcelona, ES)

/ 97


11:30 - 12:00 Barriers to brain volume measurement in the real world M. Battaglini (Siena, IT)

Teaching Courses, Hall F10:30 - 12:00 Teaching Course 9: Cognition

ChairsM.P. Amato (Florence, IT)J. DeLuca (New Orange, US)

10:30 - 11:00 Epidemiology of cognitive impairment: an update M.P. Amato (Florence, IT)

11:00 - 11:30 Current approaches to management J. DeLuca (New Orange, US)

11:30 - 12:00 Cognition as a clinical outcome measure in clinical trials on DMDs R.H. Benedict (Buffalo, US)

Teaching Courses, Hall G10:30 - 12:00 Teaching Course 10: Progressive multiple sclerosis and

the relationship to relapsing disease - how neuroglial inter-actions underlie the pathogenesis and treatment

ChairsS. Ludwin (Kingston, CA)H. Lassmann (Wien, AT)

10:30 - 11:00 Oxidative injury to glial cells and neurons as a basis for progressivedisease

H. Lassmann (Wien, AT)

11:00 - 11:30 Astrocyte patho-biology and interactions with other glia and neurons inthe development of PMS

S. Ludwin (Kingston, CA)

11:30 - 12:00 Targeting glia as the basis of treating progressive PMS V.W.W. Yong (Calgary, CA)

Satellite Symposia, Hall B12:30 - 13:30 European Charcot Foundation - Reconsidering the concept

of induction therapy

ChairsG. Comi (Milan, IT)

/ 97


12:30 - 12:50 The concept M.S. Freedman (Ottawa, CA)

12:50 - 13:10 The evidence G. Edan (Rennes, FR)

13:10 - 13:30 The problems and the future perspectives H.-P. Hartung (Düsseldorf, DE)

Teaching Courses, Hall C12:30 - 14:00 Teaching Course 11: Differential diagnoses

ChairsS. Fredrikson (Stockholm, SE)A. Siva (Istanbul, TR)

12:30 - 13:00 Diagnostic and differential diagnostic dilemmas in MS S. Fredrikson (Stockholm, SE)

13:00 - 13:30 MRI-diagnostic possibilities and pitfalls A. Siva (Istanbul, TR)

13:30 - 14:00 NMOSD including antiMOG related disorders as differential diagnoses toMS

B. Weinshenker (Rochester, US)

Teaching Courses, Hall D12:30 - 14:00 Teaching Course 12: Neuromyelitis optica spectrum

disorders

ChairsD.M. Wingerchuk (Scottsdale, US)K. Fujihara (Sendai, JP)

12:30 - 13:00 Update on pathogenesis of NMOSD K. Fujihara (Sendai, JP)

13:00 - 13:30 Diagnostic issues with AQP4-IgG-seropositive and -seronegative NMOSD D.M. Wingerchuk (Scottsdale, US)

13:30 - 14:00 Optimising treatment of NMOSD in various situations R. Marignier (Lyon, FR)

/ 97


Teaching Courses, Hall E12:30 - 14:00 Teaching Course 13: Imaging the non-MS lesion in MS

ChairsD. Reich (Bethesda, US)A. Rovira (Barcelona, ES)

12:30 - 13:00 Atypical imaging presentations of MS and other idiopathic demyelinatingdiseases

A. Rovira (Barcelona, ES)

13:00 - 13:30 Imaging the complications of MS therapies D. Reich (Bethesda, US)

13:30 - 14:00 The central vein sign on MRI P. Sati (Bethesda, US)

Teaching Courses, Hall F12:30 - 14:00 Teaching Course 14: OCT in clinical practice

ChairsS. Galetta (New York, US)L. Balcer (New York, US)

12:30 - 13:00 OCT in MS: what have we learned so far? L. Balcer (New York, US)

13:00 - 13:30 OCT in MS: what is new? S. Saidha (Baltimore, US)

13:30 - 14:00 OCT in the clinic: case by case S. Galetta (New York, US)

Teaching Courses, Meeting Room 31512:30 - 14:00 Case-based Teaching Course 15: Paediatric MS

ChairsB. Banwell (Philadelphia, US)K. Deiva (Paris, FR)

12:30 - 13:15 Case presentation 1 B. Banwell (Philadelphia, US)

13:15 - 14:00 Case presentation 2 K. Deiva (Paris, FR)

/ 97


Parallel Sessions, Hall B14:00 - 15:30 Parallel Session 1: Prevalence and phenotype evolution of

MS in different continents

ChairsP. Duquette (Montréal, CA)M.A.A. Sahraian (Tehran, IR)

14:00 - 14:20 Asia T. Yamamura (Tokyo, JP)

14:20 - 14:40 Africa-Middle East R. Gouider (Manouba, TN)

14:40 - 15:00 Latin America L. Negrotto (Buenos Aires, AR)

15:00 - 15:20 Australia / New Zealand H. Butzkueven (Melbourne, AU)

15:20 - 15:30 The clinical course, therapeutic responses, and outcomes in relapsingMOG antibody-associated demyelination

S. Ramanathan (Sydney, AU)

Young Scientific Investigators’ Sessions, Hall C14:00 - 15:30 Young Scientific Investigators' Session 1

ChairsP. Calabresi (Baltimore, US)V. Zujovic (Paris, FR)

14:00 - 14:15 Brain atrophy rates in multiple sclerosis changes along disease courseare sensitive to image processing method: not ready for NEDA-4 yet?

M. Andorrà (Barcelona, ES)

14:15 - 14:30 Altered default-mode network dynamics in cognitively impaired MSpatients

A.J. Eijlers (Amsterdam, NL)

14:30 - 14:45 Ganglion cell layer atrophy starts one week after onset of acute opticneuritis and progress over 18 months

E.H. Martinez-Lapiscina (Barcelona, ES)

14:45 - 15:00 Predicting performance improvements with visuomotor training in MSusing a multi-modal clinical and neuroimaging approach

I. Lipp (Cardiff, GB)

15:00 - 15:15 Enlargement of white matter MS lesions is associated with lesionalmicroglial activation measured in vivo

C. Benoit (Paris, FR)

/ 97


15:15 - 15:30 Independent Contributions of Cervical Cord Lesions and Thalamic,Cerebellar, and Putaminal Volumes to Upper Extremity Function in EarlyMultiple Sclerosis

A. Harel (New York, US)

Nurses Sessions, Hall E14:15 - 15:30 Nurses' Session 1

Teaching Courses, Meeting Room 31514:15 - 15:45 Case-based Teaching Course 16: Induction treatment in

very active multiple sclerosis: why, how, when?

ChairsG. Edan (Rennes, FR)E. Le Page (Rennes, FR)

14:15 - 15:00 Case presentation 1 G. Edan (Rennes, FR)

15:00 - 15:45 Case presentation 2 E. Le Page (Rennes, FR)

Teaching Courses, Meeting Room 313/31414:15 - 15:45 Case-based Teaching Course 17: Definition of non-

responders

ChairsM. Tintoré (Barcelona, ES)A. Ruet (Bordeaux, FR)

14:15 - 15:00 Case presentation 1: failing to first line treatment: NEDA vs MEDA A. Ruet (Bordeaux, FR)

15:00 - 15:45 Case presentation 2: definition on treatment response in second linetreatment: how to face pregnancy desire while being on treatment

M. Tintoré (Barcelona, ES)

Teaching Courses, Meeting Room 311/31214:15 - 15:45 Case-based Teaching Course 18: Progressive MS: Whom to

treat, with what and for how long?

ChairsB.A. Cree (San Francisco, US)

/ 97


14:15 - 15:00 Case presentation 1 B.A. Cree (San Francisco, US)

15:00 - 15:45 Case presentation 2

Hot Topic Sessions, Hall B16:00 - 16:45 Hot Topic 1: Progressive MS alliance: what’s new

ChairsW.M. Carroll (Nedlands, AU)A.J. Thompson (London, GB)

16:00 - 16:15 Selected project D.L. Arnold (Montréal, CA)

16:15 - 16:30 Selected project G. Martino (Milan, IT)

16:30 - 16:45 Development of a drug discovery pipeline for secondary progressive MS F.J. Quintana (Boston, US)

Young Scientific Investigators’ Sessions, Hall C16:00 - 17:15 Young Scientific Investigators' Session 2

ChairsM. Comabella (Barcelona, ES)S. Zamvil (San Francisco, US)

16:00 - 16:15 Loss of tolerance of thyroid-specific B cells as a biomarker for increasedrisk for AITD in anti-CD52 treated MS patients

M.J. Smith (Aurora, US)

16:15 - 16:30 Propionic acid modulates T effector cell balance and function in MSpatients

A. Duscha (Bochum, DE)

16:30 - 16:45 Proposed NASSC Classification Criteria Provide labels for Patients withearly Susac Syndrome but do not meet EuSaC Diagnostic Criteria

G.R. Paton (Vancouver, CA)

16:45 - 17:00 Different patterns of structural and microstructural damage inNeuromyelitis Optica Spectrum Disorders

A. d'Ambrosio (Milan, IT)

17:00 - 17:15 Monitoring treatment response in MS by serum NFL reflect treatmentefficacy

L. Novakova (Gothenburg, SE)

/ 97


Hot Topic Sessions, Hall D16:00 - 16:45 Hot Topic 2: e-MS and patients related outcomes

ChairsM. Trojano (Bari, IT)P.A. Gourraud (San Francisco, US)

16:00 - 16:15 Interests and needs of health intervention technology in chronicdiseases

T. Ziemssen (Dresden, DE)

16:15 - 16:30 Apps in monitoring MS J. Alberts (Cleveland, US)

16:30 - 16:45 Pros and cons of web based outcomes measures to monitor diseaseprogression

G. Giovannoni (London, GB)

Nurses Sessions, Hall E16:00 - 17:15 Nurses' Session 2

Satellite Symposia, Hall A17:30 - 18:30 Satellite Symposium - Can real world evidence (RWE)

deliver personalised medicine?

Supported by Biogen International

ChairsS. Vukusic (Lyon, FR)

Satellite Symposia, Hall A18:45 - 19:45 Satellite Symposium - Understanding Neuropreservation:

How does it translate to clinical outcomes?

Supported by Sanofi Genzyme

ChairsG. Edan (Rennes, FR)

18:45 - 18:50 Introduction G. Edan (Rennes, FR)

18:50 - 19:15 How is neuropreservation in MS evaluated? F. Barkhof (Amsterdam, NL)

19:15 - 19:40 Preserving brain and improving clinical outcomes: how are they related? A. Traboulsee (Vancouver, CA)

/ 97


19:40 - 19:45 Close G. Edan (Rennes, FR)

/ 97


Thursday, 26 October 2017

Satellite Symposia, Hall D07:45 - 08:45 Satellite Symposium - New horizons in progressive

Multiple Sclerosis

Supported by MedDay Pharmaceuticals

ChairsJ. Antel (Montreal, CA)D.J. Mahad (Edinburgh, GB)

07:45 - 08:00 New classification and challenges in Progressive MS B.A. Cree (San Francisco, US)

08:00 - 08:10 Update on mechanisms involved in neuronal degeneration M. Kerschensteiner (Munich, DE)

08:10 - 08:20 Innovation in Progressive MS: the metabolic approach O. Gout (Paris, FR)

08:20 - 08:30 Rehabilitation in Progressive MS: from evaluation to treatment M. Haupts (Isselburg-Anholt, DE)

08:30 - 08:45 Q&A and closure of the meeting

Plenary Sessions, Hall A09:00 - 10:15 Plenary Session 1 Welcome Addresses and ECTRIMS

Lecture

ChairsD. Miller (London, GB)C. Lubetzki (Paris, FR)

09:00 - 09:30 Welcome to MSParis2017

09:30 - 10:15 ECTRIMS-ACTRIMS Opening Lecture: From neuropathology to new patho-physiological concepts and clinical perspectives

H. Lassmann (Wien, AT)

Parallel Sessions, Hall A10:45 - 12:15 Parallel Session 2: The new MS criteria

ChairsA.H. Cross (St. Louis, US)S. Chandran (Edinburgh, GB)

/ 97


10:45 - 11:05 Evaluation of MS diagnostic criteria J.A. Cohen (Cleveland, US)

11:05 - 11:25 Impact of the new criteria on disease management J. Chataway (London, GB)

11:25 - 11:37 The added value of oligoclonal bands in the multiple sclerosis diagnosticcriteria

G. Arrambide (Barcelona, ES)

11:37 - 11:49 Revised McDonald 2010 versus MAGNIMS 2016 MRI criteria in CISpatients suggestive of MS: a multicenter study

M. Filippi (Milano, IT)

11:49 - 12:01 Impact of including optic nerve lesions in dissemination in space indiagnostic criteria for multiple sclerosis

W.J. Brownlee (London, GB)

12:01 - 12:13 Comparative evaluation of successive criteria for neuromyelitis optica R. Marignier (Lyon, FR)

Parallel Sessions, Hall B10:45 - 12:15 Parallel Session 3: Update on MS prognostic markers

ChairsD. Brassat (Toulouse, FR)C. Teunissen (Amsterdam, NL)

10:45 - 11:05 Prognostic biomarkers in MS E. Thouvenot (Nîmes, FR)

11:05 - 11:25 Prognostic imaging markers of MS C. Azevedo (Los Angeles, US)

11:25 - 11:37 New spinal cord and infratentorial lesions in early relapse-onset MS arepredictive of secondary progressive disease course after 15 years

W.J. Brownlee (London, GB)

11:37 - 11:49 Temporal Variability Profile of Serum Neurofilament Light Levels inMultiple Sclerosis Patients

P. Calabresi (Baltimore, US)

11:49 - 12:01 Association between psychiatric comorbidity and disability progressionof multiple sclerosis

K.A. McKay (Vancouver, CA)

12:01 - 12:13 Structural MRI predictors of cognitive decline in MS A.J. Eijlers (Amsterdam, NL)

/ 97


Parallel Sessions, Hall C10:45 - 12:15 Parallel Session 4: Axon/myelin injury in MS lesions and

experimental models

ChairsM. Friese (Hamburg, FR)P. Stys (Calgary, CA)

10:45 - 11:05 Immune mediated injury of axon-myelin unit M. Simons (Göttingen, DE)

11:05 - 11:25 Evolution of the MS plaques C. Lucchinetti (Rochester, US)

11:25 - 11:37 Connexins in Neuromyelitis Optica : a link between astrocytopathy anddemyelination

C. Richard (Lyon, FR)

11:37 - 11:49 Influx of extracellular calcium drives axonal degeneration in an animalmodel of multiple sclerosis

M.E. Witte (Munich, DE)

11:49 - 12:01 The staging of astrocytopathy in neuromyelitis optica spectrum disorderswith aquaporin4-IgG

Y. Takai (Sendai, JP)

12:01 - 12:13 Evaluation of the neuroprotective properties of alpha-lipoic acid byoptical coherence tomography in a model of experimental autoimmuneencephalomyelitis-optic neuritis

P. Albrecht (Düsseldorf, DE)

Parallel Sessions, Hall D10:45 - 12:15 Parallel Session 5: The blood brain barriers in MS

ChairsK. Akassoglou (San Francisco, US)P.-O. Couraud (Paris, FR)

10:45 - 11:05 Immune cell trafficking across the CNS barriers in MS B. Engelhardt (Berne, CH)

11:05 - 11:25 Blood brain barrier adhesion molecules as therapeutic targets in MS A. Prat (Montreal, CA)

11:25 - 11:37 Integrin alpha8 is a novel mediator of proinflammatory T lymphocytemigration across the CNS barriers

E.M. Gowing (Montreal, CA)

11:37 - 11:49 Antigen expression by endothelial cells of the blood brain barrier elicitsactivation and pathogenicity of CD8 T cells in the central nervous system

C. Meyer (Toulouse, FR)

/ 97


11:49 - 12:01 EGFL7 is a novel player in multiple sclerosis that beneficially regulatesCNS infiltration

C. Larochelle (Montreal, CA)

12:01 - 12:13 Astrocytic tight junctions control inflammatory CNS lesion pathogenesis C. Chapouly (New York, US)

Satellite Symposia, Hall A13:00 - 14:00 Satellite Symposium - Emerging landscape of the next

generation of MS therapies: current efforts Remylinationand Neurorestoration

Supported by AbbVie

ChairsB.A. Cree (San Francisco, US)G. Giovannoni (London, GB)

Satellite Symposia, Hall B13:00 - 14:00 Satellite Symposium

Supported by Roche

Parallel Sessions, Hall A14:00 - 15:30 Parallel Session 6: Therapeutic perspectives in

progressive MS

ChairsR. Kapoor (London, GB)J.S. Wolinsky (Houston, US)

14:00 - 14:20 Prognostic factors in progressive MS G. Edan (Rennes, FR)

14:20 - 14:40 Therapeutic advances and failures in progressive MS F. Lublin (New York, US)

14:40 - 14:52 The effect of disease-modifying treatments on conversion to secondaryprogressive multiple sclerosis

J.W.L. Brown (Cambridge, GB)

14:52 - 15:04 Effects of Siponimod on MRI Outcomes in Patients With SecondaryProgressive Multiple Sclerosis: Results of the Phase 3 EXPAND Study

R.J. Fox (Cleveland, US)

/ 97


15:04 - 15:16 MD1003 in Progressive Multiple Sclerosis: 24-Month Brain MRI Results ofthe MS-SPI Trial

D.L. Arnold (Montréal, CA)

15:16 - 15:28 Natalizumab improves walking and upper-limb disability compared withplacebo in patients with secondary progressive multiple sclerosis: anintegrated, post hoc area under the outcome-time curve analysis fromthe ASCEND trial


Parallel Sessions, Hall B14:00 - 15:30 Parallel Session 7: Paediatric MS

ChairsA. Boyko (Moscow, RU)M. Tardieu (Paris, FR)

14:00 - 14:20 Long term prognosis of pediatric MS R. Hintzen (Rotterdam, NL)

14:20 - 14:40 Treatment of pediatric MS E. Waubant (San Francisco, US)

14:40 - 14:52 Regional grey matter atrophy in pediatric patients with multiplesclerosis: a longitudinal MRI study

E. De Meo (Milan, IT)

14:52 - 15:04 Cognitive reserve is associated with better cognitive outcome and socio-professional attainment in both adult and pediatric-onset multiplesclerosis

L. Pasto' (Florence, IT)

15:04 - 15:16 Effect of age and gender on disease progression in pediatric multiplesclerosis population

M. Gurevich (Ramat-Gan, IL)

15:16 - 15:28 Serial MRI detects presence and evolution of a ‘surface-in’ gradient ofthalamic damage in paediatric-onset MS, which is recapitulated in adultMS autopsy

G. Fadda (Montreal, CA)

Parallel Sessions, Hall C14:00 - 15:30 Parallel Session 8: Immune cells in injury and repair

ChairsF. Zipp (Mainz, DE)A. Bar-Or (Philadelphia, US)

14:00 - 14:20 New insight into immune related CNS injury L. Steinman (Standford, US)

/ 97


14:20 - 14:40 Influence of immune cells on CNS repair M. Schwartz (Rehovot, IS)

14:40 - 14:52 Adaptive immunity drives remyelination failure or success in multiplesclerosis

C. Sanson (Paris, FR)

14:52 - 15:04 Patterns of Microglia/Macrophage Polarization in Multiple Sclerosis andStroke Lesions

T. Zrzavy (Vienna, AT)

15:04 - 15:16 Unexpected role of neutrophil granulocytes during both murine andhuman central nervous system autoimmunity

B. Knier (München, DE)

15:16 - 15:28 B cell-mediated experimental CNS autoimmunity is modulated byinhibition of Bruton’s tyrosine kinase

S. Torke (Goettingen, DE)

Parallel Sessions, Hall D14:00 - 15:30 Parallel Session 9: New insight into grey matter pathology

in MS

ChairsC. Stadelmann (Göttingen, DE)B. Trapp (Cleveland, US)

14:00 - 14:20 Synaptic pathology in cortex of multiple sclerosis D. Merkler (Geneva, CH)

14:20 - 14:40 Connection between inflammation and cortical neuronal pathology in MSand EAE

D. Centonze (Rome, IT)

14:40 - 14:52 The axon initial segment: a novel site of neuronal dysfunction in MultipleSclerosis

M. Davenne (Paris, FR)

14:52 - 15:04 Thalamic MRI and histopathologic correlations in advanced multiplesclerosis

K. Mahajan (Cleveland, US)

15:04 - 15:16 Neural Correlates of Cognitive Phenotypes in Multiple Sclerosis S.N. Levin (Boston, US)

15:16 - 15:28 Meningeal inflammation is linked to subpial cortical demyelination inprogressive multiple sclerosis with ongoing white matter pathology

V. Ramaglia (Amsterdam, NL)

/ 97


Poster Sessions, Poster Exhibition Poster Session 1

Diagnostic criteria for Susac Syndrome M. Ringelstein (Düsseldorf, DE)

Time influences the performance of diagnostic criteria for multiple sclerosis W.J. Brownlee (London, GB)

Evaluation of the sensitivity of the 2016 MAGNIMS MRI criteria for dissemination in space inchildren

Y. Hacohen (London, GB)

Lesion topographies in the multiple sclerosis diagnostic criteria: a reappraisal B. Arrambide (Barcelona, ES)

Brain and spinal cord imaging features in neuromyelitis optica spectrum disorder L. Cacciaguerra (Milan, IT)

Performance of 2010 McDonald criteria and 2016 MAGNIMS guidelines in the diagnosis ofprimary progressive multiple sclerosis

A. Gajofatto (Verona, IT)

Brain microglial activation detected by TSPO PET at the pre-symptomatic stage of MS E. Poirion (Paris, FR)

Clinical and prognosis profile of paraneoplastic neuromyelitis optica spectrum disorders N. Sola-Valls (Barcelona, ES)

Susac Syndrome: Clinical Features, laboratory testing and treatment responses of 20 cases C. Boz (Trabzon, TR)

Epidemiology of neuromyelitis optica spectrum disorders in Catalonia: a population-basedstudy

A. Saiz (Barcelona, ES)

Double seronegative longitudinally extensive transverse myelitis: preliminary study on 17patients

E. Maillart (Paris, FR)

IMMUNOGLOBULIN FREE LIGHT CHAINS IN SALIVA: A new marker of multiple sclerosis? E. Ganelin-Cohen (Petach Tikva, IL)

Application of the 2015 diagnostic criteria for Neuromyelitis Optica Spectrum Disorders in acohort of Latin American patients: the impact on diagnostic rates

E.G. Carnero Contentti (Buenos Aires, AR)

A molecular-based approach using long, non-coding RNA and enhancer-associated lncRNAgene expression signatures to classify multiple sclerosis using peripheral whole blood

C.F. Spurlock, III (Nashville, US)

New Possibilities in Multiple Sclerosis Imaging Evaluation: studying the performance ofPhase Sensitive Inversion Recovery (PSIR) in juxtacortical lesions

M.C.A. Vecino (Porto Alegre, BR)

/ 97


Myelin oligodendrocyte glycoprotein antibodies predict a favourable outcome inneuromyelitis optica related disorders

A. Cobo-Calvo (Lyon, FR)

Myelin oligodendrocyte glycoprotein antibodies spectrum disorder: clinical features andprognostic factors in a cohort of 150 adult patients

A. Cobo-Calvo (Lyon, FR)

Prognostic factor for therapeutic response of attacks in anti-AQP4, anti-MOG seropositiveand NMO seronegative patients

N. Collongues (Strasbourg, FR)

Complement activation is associated with microscopic pathology in the placentas of womenwith NMO

R. Bove (San Francisco, US)

Neuromyelitis Optica Spectrum Disorders: 20-year single centre observational data withtreatment analysis

D.B. Bichuetti (Sao Paulo, BR)

Anti-MOG antibodies induce complement mediated demyelination in isolated optic neuritisand myelitis

C. Tortorella (Bari, IT)

Ethnic differences in clinical manifestation and outcome of neuromyelitis optica spectrumdisorder

S.-H. Kim (Goyang, KR)

Clinical, MRI and laboratory features of myelin oligodendrocyte glycoprotein(MOG)-antibody-associated neurologic disease: a study of 259 cases

K. Kaneko (Sendai, JP)

NMOSD relapses: an analysis of 328 episodes in 75 cases S.A. Broadley (Griffith University, AU)

Multiple Sclerosis AHI1 Genetic Risk Promotes IFNg+ CD4+ T Cells W. Elyaman (New York, US)

Double inversion recovery MRI in the evaluation of the anterior visual pathway in patientswith multiple sclerosis and neuromyelitis optica spectrum disorders

E. Saji (Niigata, JP)

“What could be the clinical and MRI spectrum of anti-MOG associated disorders?” V. Papp (Aarhus, DK)

Disease course and immunotherapies responses in children with relapsing myelinoligodendrocyte glycoprotein antibodies (MOG-Ab)-associated disease

Y. Hacohen (London, GB)

Psychiatric morbidity develops after onset of pediatric multiple sclerosis: a Danishnationwide population-based study

M.S. Boesen (Copenhagen, DK)

/ 97


Childhood multiple sclerosis is associated with reduced brain volumes at disease onset andbrain growth failure

F. Bartels (Berlin, DE)

Executive dysfunction in paediatric-onset multiple sclerosis: Deficits above and beyondslowed processing speed

E. Barlow-Krelina (Toronto, CA)

Clinical significance of anti-MOG antibodies in the evaluation of children with a firstdemyelinating episode: prospective Spanish national cohort

T. Armangue (Barcelona, ES)

Implications of the International Paediatric Multiple Sclerosis Study Group consensuscriteria for paediatric acute disseminated encephalomyelitis: a Danish nationwidepopulation-based study


Continuous Accelerometry as a Measure of Physical Activity Impairment in Paediatric-OnsetMultiple Sclerosis Subjects Versus Healthy Controls

J.N. Brenton (Charlottesville, US)

Chitinase 3-like 1 and neurofilament light chain in the cerebrospinal fluid predict pediatricacquired CNS demyelinating disease


Evaluation of Teriflunomide in Children and Adolescents With Relapsing MS: TERIKIDS Phase3 Study Design, Enrolment Update, and Baseline Data

T. Chitnis (Boston, US)

Risk of secondary progressive multiple sclerosis: a longitudinal study T. Kalincik (Melbourne, AU)

Characteristics of Radiologically isolated syndrome (RIS) national French Cohort C. Lebrun-Frenay (Nice, FR)

Predicting MS disease progression remains a significant challenge: Results from advancedstatistical models of RCT placebo arms

M. Copetti (S. Giovanni Rotondo, IT)

Looking back: patients with “Aggressive MS” (EDSS 6.0 at 10 years) in the Barcelona CIScohort

M. Tintoré (Barcelona, ES)

Miscarriage induces reactivation of inflammation in relapsing-remitting Multiple Sclerosis D. Landi (Rome, IT)

How common is truly benign MS? E.C. Tallantyre (Cardiff, GB)

Long Term Outcomes of Neuromyelitis Optica: A Systematic Literature Review Z. Nasr (Rochester, US)

Description of patients with benign multiple sclerosis in the treatment era A. Bouley (Providence, US)

/ 97


Cognitive impairment can help to predict long-term disease course in benign multiplesclerosis patients: a 12 year follow-up study

L. Razzolini (Florence, IT)

Long-term treatment effect over disability progression in patients with relapsing multiplesclerosis

B. Casanova Estruch (València, ES)

Increased incidence of psychiatric disorders five years before diagnosis in multiple sclerosis R.A. Marrie (Winnipeg, CA)

A large cohort study of physical and psychological impacts of smoking on PwMS via the UKMS Register

J. Rodgers (Swansea, GB)

A nationwide survey of the influence of month of birth on the risk of developing multiplesclerosis in Sweden and Iceland

O. Eliasdottir (Gothenburg, SE)

Observatoire Français de la Sclérose en Plaques (OFSEP): a powerful epidemiological tool R. Casey (Lyon, FR)

The Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS)patient cohort

E.M. Mowry (Baltimore, US)

Social networks in persons at risk for developing multiple sclerosis P. De Jager (New York, US)

Decline in PPMS Diagnosis? – The German View D. Ellenberger (Göttingen, DE)

Concussion in adolescence and multiple sclerosis risk T. Olsson (Stockholm, SE)

Clinical Characteristics and Treatment Patterns of Relapsing-Remitting Multiple SclerosisPatients with High Disease Activity

T. Spelman (Parkville, AU)

Factors impacting mortality rates in a large French Canadian MS population: A review of 4decades of data

M.-C. Rousseau (Laval, CA)

Understanding the timing of environmental exposures in the risk of MS B. Taylor (Hobart, AU)

Determining the incidence of MS in a Swedish county – overcoming challenges in usingregistry data

I. Boström (Linköping, SE)

The Prevalence of Multiple Sclerosis in the United States: A Population-Based HealthcareDatabase Approach

M.T. Wallin (Washington, US)

/ 97


A population-based assessment of “no evident disease activity” (NEDA) in multiple sclerosis N.E. Parks (Rochester, US)

Use of the new oral disease-modifying therapies among the multiple sclerosis population inBritish Columbia, Canada over a five-year period (2011-2015)

S. Setayeshgar (Vancouver, CA)

Incidence and follow-up of acquired demyelinating syndromes in Dutch children – update ofa nationwide and prospective study

C.L. de Mol (Rotterdam, NL)

The Association between Disease Activity and Disability Progression in Patients withRelapsing-Remitting Multiple Sclerosis


Sex related differences of fetal maternal cross-talk modify phenotypic characteristics inwomen with multiple sclerosis

P. Ragonese (Palermo, IT)

Harnessing Electronic Medical Records to Advance Research on Multiple Sclerosis V. Damotte (San Francisco, US)

Comparison of case-mix in multiple sclerosis patients participating in randomized controltrials, prospective observational studies, and Multiple Sclerosis Partners AdvancingTechnology and Health Solutions (MS PATHS)

F. Pellegrini (Zug, CH)

Assisted reproductive technologies and relapse risk: a new case series, and pooled analysisof existing studies


Pregnancy incidence and therapy exposure in relapsing forms of MS: a 12-yearretrospective multicentre analysis

V.G. Jokubaitis (Parkville, AU)

Alemtuzumab and pregnancy – A case series from the German MS and Pregnancy Registry – K. Hellwig (Bochum, DE)

X chromosome wide association analysis identified a novel FRMPD4 locus that differentiallyeffects MS risk by sex

Y. Zhou (Hobart, AU)

Infertility Diagnosis and Treatment in Women With and Without Multiple Sclerosis M.K. Houtchens (Brookline, US)

Neonatal and delivery outcomes of babies to mothers with multiple sclerosis in Sweden K. Fink (Solna, SE)

Unplanned Pregnancy Risk in a United States Multiple Sclerosis Patient Cohort A.L. Smith (Cleveland, US)

Randomized Controlled Trial of two group programs in Multiple Sclerosis: 12-month (Long-term) follow-up effects on fatigue and self-efficacy

C. Hugos (Portland, US)

/ 97


Abdominal massage in the self-management of constipation in people with multiplesclerosis

D. McClurg (Glasgow, GB)

Perceived cognitive function in people with MS and its relationship to objectiveneuropsychological measurement with BICAMS

N. McNicholas (Dublin, IE)

Cognitive impairment and brain atrophy in multiple sclerosis; a 10-year follow-up study C.O. Jacobsen (Stavanger, NO)

Factors that affect computerized cognitive screening in people with MS: diurnal variation,location and practice effects

D. Merlo (Melbourne, AU)

Fatigue acceptance mediates cross-sectional and longitudinal associations between fatigueand sleep disturbance in multiple sclerosis

A.J. Hughes (Baltimore, US)

Self-reported sleep disturbance and cognitive function in MS: Mediating effects ofdepressed mood and fatigue

A.J. Hughes (Baltimore, US)

Repeatability and validity of neurophysiological correlates of fatigue in people with multiplesclerosis

P.M. Ellison (Newcastle Upon Tyne, GB)

Depressive symptoms are associated with more negative functional outcomes than anxietysymptoms in persons with multiple sclerosis

S.A. Morrow (London, CA)

Neuroradiological characterization of multiple sclerosis patients with chronic pain D. Plantone (Rome, IT)

Objective speech marker correlates with clinical scores in non-dysarthric MS G. Noffs (Melbourne, AU)

Cognitive flexibility in Multiple sclerosis patients may be dependent on informationprocessing speed

K. Zebenholzer (Vienna, AT)

Association between self-reported upper limb, lower limb and cognitive functioning andfunctional performance in MS PATHS (Multiple Sclerosis Partners Advancing Technology andHealth Solutions) patients

D. Miller (Cleveland, US)

Factors associated with Fatigue in the NARCOMS Registry A. Salter (St. Louis, US)

Factors driving social withdrawal across multiple sclerosis disease types R.J. Mills (Preston, GB)

The Expanded Timed Get Up and Go is a more sensitive predictor of disability than theTimed 25-foot walk in people with multiple sclerosis

B. Weinstock-Guttman (Buffalo, US)

/ 97


Intensive neurorehabilitation is associated with improved gait kinematic analysis inprogressive multiple sclerosis

C. Zanetta (Milano, IT)

Can we trust self-reported walking distance when determining EDSS scores? – A part of theDanish MS Hospitals Rehabilitation Study

A.G. Skjerbaek (Ry, Haslev, DK)

Continuous Wrist-Worn Accelerometry Captures Change in Average Daily Step Count inPeople with Multiple Sclerosis Over One Year

V.J. Block (San Francisco, US)

Convergent Validity of Acceleration-Derived Parameters from iPad®-based Walking andBalance Testing

F. Bethoux (Cleveland, US)

McArdle sign: a specific sign of multiple sclerosis B. Weinshenker (Rochester, US)

How useful is the Hospital Anxiety and Depression Scale (HADS) in multiple sclerosis? V.P. Patel (Toronto, CA)

Subclinical motor impairment assessed by an engineered glove correlates with MRI braindamage in radiologically isolated syndromes

L. Bonzano (Genoa, IT)

Reliability and validity of a new, sensor-based system for gait analysis in patients withmultiple sclerosis

F. Flachenecker (Erlangen, DE)

Risk Factors for Cognitive Impairment in Multiple Sclerosis as Defined by the Symbol DigitModalities Test: A Retrospective Analysis of the University of Calgary Multiple SclerosisClinic Database

T. Brust (Calgary, CA)

Fully automated detection, segmentation and quantification of mean cross-sectional area ofthe spinal cord

F. Weiler (Bremen, DE)

Decreased articulation rate in multiple sclerosis and its relationship to overall diseasedisability and cognitive function

B. Benova (Prague, CZ)

Phonatory dysfunction in multiple sclerosis B. Benova (Prague, CZ)

Assessing upper extremity function and mobility with multiple clinical tests of the AssessMS system

C.E. van Munster (Amsterdam, NL)

Disability measures used in multiple sclerosis patients: correlations with MRI-derived globaland microstructural damage

D. Jakimovski (Buffalo, US)

/ 97


A Comparison of participant supplied EDSS scores and clinically submitted data via the UKMS Register

R.M. Middleton (Swansea, GB)

Information Processing Speed on the SDMT is Predicted by Saccadic Eye MovementDysfunction in Patients with Multiple Sclerosis

N. Pawlak (New York, US)

Validation of Automated Cortical and Subcortical Multiple Sclerosis Lesion Detection Using aSingle 7T MP2RAGE Scan

M.J. Fartaria (Lausanne, CH)

Validity of routine administration of Neuro-QoL in Multiple Sclerosis Partners AdvancingTechnology and Health Solutions (MS PATHS)

A. Boster (Columbus, US)

Reliability of BICAMS (Arabic version) in Egyptian Multiple Sclerosis patients N. Kishk (Cairo, EG)

Timed up and go and brain atrophy: a preliminary MRI study to assess functional mobilityperformance in Multiple Sclerosis

L. Lorefice (Cagliari, IT)

An investigation into the cognitive impact on physical disability in the community in peoplewith Multiple Sclerosis (PwMS)

M. Gudesblatt (Patchogue, US)

Health-related quality of life attributes associated with work productivity loss and caregiverburden in multiple sclerosis

C. Hategeka (Vancouver, CA)

The Burden of Relapsing Remitting Multiple Sclerosis on Workers in the United States J. Nicholas (Columbus, US)

Estimating MS-related work productivity loss and factors associated with labour forceparticipation in a representative Australian sample of people with multiple sclerosis

J. Chen (Hobart, AU)

Multiple sclerosis relapses: budget impact analysis of oral high-dose corticosteroids D. Veillard (Rennes, FR)

The changing landscape of Disease Modifying Treatments: cost implications for healthcaresystems

A. Zarkali (Canterbury, GB)

Pattern ERG related to ganglion cell loss and impaired visual function in patients multiplesclerosis

H. Jiang (Miami, US)

Mapping focal loss of the ganglion cell–inner plexiform layer in patients multiple sclerosis J. Wang (Miami, US)

Outer retinal function and structure in multiple sclerosis J.V.M. Hanson (Zurich, CH)

/ 97


Temporal dynamics of structural and functional retinal damage in acute optic neuritis C.A. Wicki (Zurich, CH)

A new, sensitive visual test for the diagnosis of acute optic neuritis G. Pihl-Jensen (Glostrup, DK)

Self-monitoring visual function via a smartphone application N. Dubuisson (London, GB)

The impact of depression and anxiety symptoms on information processing speed in MS andother immune-mediated inflammatory diseases

C. Whitehouse (Halifax, CA)

Movement disorders in demyelinating diseases C. Candeias da Silva (Sao Paulo, BR)

A change in multiple sclerosis morbidity spectrum R. Hernandez Clares (Murcia, ES)

Self-reported smoking status associated with clinical disease worsening in CombiRx S.S. Cofield (Birmingham, US)

Neuropsychological impairment in newly diagnosed early multiple sclerosis: clinical andneuropsychological characterization of a German cohort of 1124 patients

A. Salmen (Bochum, DE)

Altered grey matter networks in young patients with MS at genetic risk for Alzheimer’sdisease

G. Gonzalez-Escamilla (Mainz, DE)

Prevalence of Restless Legs Syndrome/Willis-Ekbom Disease in Multiple Sclerosis: a case-control study in Argentina


Prevalence of sleep apnea in multiple sclerosis patients meeting clinical eligibility criteriafor the Sleep Apnea in Multiple Sclerosis Positive Airway Pressure (SAMSPAP) trial

S. Khadadah (Montreal, CA)

Excess of Neurological And Psychiatric Comorbidity in Multiple Sclerosis Patients asCompared to the General Population in Catalonia (Spain)

M.-A. Passarell (Barcelona, ES)

Blockade of MCAM on TH17 cells impedes their CNS infiltration over the choroid plexus J. Breuer (Münster, DE)

Paraneoplastic Neuromyelitis Optica: an update on a single center cohort with cases ofhistological validation

R. Carruthers (Vancouver, CA)

Inflammation effectively eliminates JC virus during progressive multifocalleukoencephalopathy

L. Stork (Göttingen, DE)

Alterations of minicolumnar cytoarchitecture and axonal loss in Multiple Sclerosis cortex M. Vercellino (Torino, IT)

/ 97


The impact of high level of perivenular inflammation on active white matter lesions anddisease progression in multiple sclerosis

R. Magliozzi (Verona, IT)

Neuromyelitis optica: Distinct staining patterns of sera containing AQP4- and MOG-antibodies in the murine visual system

F. Graz (Bochum, DE)

Focal cortical astrocytopathy lesions with demyelination and inflammatory cell infiltrates inneuromyelitis optica spectrum disorder: a neuropathological study of eleven autopsiedcases

S. Hayashida (Fukuoka, JP)

In vivo Modeling of the Nascent Multiple Sclerosis Lesion: Epsilon toxin Induced Mechanismsof Blood Brain Barrier Permeability

J.R. Linden (New York, US)

Focal overexpression of FGF9 in rat cortex induces de- and dysmyelination C. Wrzos (Goettingen, DE)

Neutrophils mediate blood-brain barrier disruption in a rat model of neuromyelitis optica A. Winkler (Göttingen, DE)

Critical role of GM-CSF, not IL-17, in relapsing experimental auto-immune encephalomyelitis L. D'Auria (Chicago, US)

Subtle biochemical myelin pathology triggers secondary inflammatory demyelination inmouse brain

A.V. Caprariello (Calgary, CA)

Visual evoked potentials reflect optic nerve demyelination in EAE S. Marenna (Milan, IT)

Amelioration of Secondary Progressive Experimental Autoimmune Encephalomyelitis byRestoring Mitochondrial Energy Production in a GOT2-dependent Manner

M. Kinoshita (Osaka, JP)

Immunomodulatory therapy in genetic mouse models of progressive multiple sclerosis J. Groh (Wuerzburg, DE)

Glunomab®: a novel “barrier-protecting” monoclonal antibody efficient in mouse models ofEAE

F. Docagne (Caen, FR)

Transcriptomic Analysis of Disease Reversal in EAE: Comparison of Laquinimod and FTY-720 J. Kaye (Netanya, IL)

Potential beneficial effect of neuroinflammation on experimental stroke K. Guse (Bern, CH)

Optical Coherence Tomography Identifies Structural Retinal Damage in ExperimentalAutoimmune Encephalomyelitis

P. Manogaran (Zurich, CH)

/ 97


Diffusion tensor imaging of the afferent visual pathway as an in vivo tool to assessneurodegeneration in experimental autoimmune encephalomyelitis

C. Egger (Zurich, CH)

MicroRNA-146a deficiency protects against cuprizone-induced demyelination Z. Illes (Odense, DK)

Investigating blood-brain barrier integrity, immune cell infiltration and disease-relatedgender differences in a spontaneous transgenic mouse model for multiple sclerosis

C. Lachance (Montreal, CA)

IL-15 enhances pro inflammatory T cell responses in multiple sclerosis and experimentalautoimmune encephalomyelitis

C. Laurent (Montreal, CA)

Preferential axonal accumulation of mitochondria during cuprizone-induced demyelination S. Schmutz (Munich, DE)

Development of an in vitro myelination assay using mouse oligodendrocytes and a 3Dscaffold of engineered nanofibers

Y. Yang (Cleveland, US)

Effect of Ozanimod (RPC1063) on Action Potential Parameters in Adult Human PurkinjeFibres

N. Abi-Gerges (San Diego, US)

Differential effects of primary and secondary progressive MS cerebrospinal fluid on motorfunction and spinal cord pathology

J.K. Wong (New York, US)

NINJ2 as a novel protein involved in response to Interferon-β in Multiple Sclerosis S. Peroni (Milan, IT)

An alternatively spliced isoform of HLA-DRA may be implicated in multiple sclerosis V. Damotte (San Francisco, US)

Association of smoking but not HLA-DRB1*15:01, APOE, or body mass index with brainatrophy in early multiple sclerosis

F. Luessi (Mainz, DE)

A whole-genome sequencing study associates GRAMD1B with Multiple Sclerosis risk anddisease activity

F. Martinelli Boneschi (Milan, IT)

Genotype is predicting Multiple Sclerosis lesion activity in autopsy cohort of theNetherlands Brain Bank

N.L. Fransen (Amsterdam, NL)

Investigating the role of the major histocompatibility complex on multiple sclerosis in anadmixed Hispanic population

A. Beecham (Coral Gables, US)

A genetic risk variant for multiple sclerosis modulates the processing of CD58 mRNA andmicroRNA-548ac from the same transcript

N. Boxberger (Rostock, DE)

/ 97


Expression Profile of Long Non-Coding RNAs (lncRNAs) in Serum of Patients withProgressive Multiple Sclerosis

V. Nociti (Rome, IT)

An integrated candidate gene study of response to fingolimod in relapsing remittingmultiple sclerosis patients

F. Esposito (Milan, IT)

Understanding Progression in Multiple Sclerosis through Transcriptomics and DNAMethylation in CD4+ and CD8+ T Cells

S. Fernandes (Solna, SE)

DICAM: a new player in Multiple Sclerosis pathogenesis C. Grasmuck (Montreal, CA)

Non-canonical autophagy drives CD4+ T cell reactivation during autoimmune CNSinflammation

C.W. Keller (Zurich, CH)

The TH17-associated cytokine IL-26 enhances BBB integrity: Implications for MS E. Peelen (Montreal, CA)

CNS-transmigration of distinct B-cell subsets through the choroid plexus in patients withmultiple sclerosis

J. Haas (Heidelberg, DE)

Gene-expression analysis of blood memory CD8+T cells at the single-cell level reveals aspecific pattern of clonally expanded cells in multiple sclerosis patients

E. Dugast (Nantes, FR)

Microglia engulf invading living Th17 cells during neuroinflammation B. Wasser (Mainz, DE)

Persistent Clonally Related CSF B Cells in Multiple Sclerosis: A longitudinal immunerepertoire study

A.L. Greenfield (San Francisco, US)

The nuclear receptor Nur77 restricts T cell responses and limits central nervous systemautoimmunity

L. Klotz (Münster, DE)

Anti-MOG antibodies from NMO-SD patients facilitate low dose antigen recognitionpromoting activation of peripheral auto-reactive T cells

S. Kinzel (Göttingen, DE)

Progressive Multiple Sclerosis: Selective involvement of the CD30/CD153 signalling pathwayin innate immunity

R. Carruthers (Vancouver, CA)

Metabolic Control of Macrophage-Mediated Myelin Phagocytosis: Implications for MultipleSclerosis

Y.H. Lin (Montreal, CA)

/ 97


Activation of the aryl hydrocarbon receptor in dendritic cells is sufficient for the UV-B-induced amelioration of experimental autoimmune encephalomyelitis

N. Mykicki (Münster, DE)

Fingolimod-induced changes in the peripheral immune repertoire and their potential asbiomarkers of treatment response in multiple sclerosis

M. Ghadiri (Montreal, CA)

Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells I. Smets (Leuven, BE)

Insulin and leptin impair regulatory T cell function in obese multiple sclerosis patients J. Correale (Buenos Aires, AR)

Histone deacetylase SIRT1 mediates C5b-9-induced cell cycle in oligodendrocytes A. Tatomir (Baltimore, US)

CD70 expression defines a subset of pro-inflammatory and pathogenic T cells that areimplicated in multiple sclerosis

T. Dhaeze (Montréal, CA)

Amplified STAT phosphorylation signaling in peripheral blood mononuclear cells from MSpatients in response to interferon alpha

E. Canto (San Francisco, US)

Role of Intestinal IgA-producing cells at regulating Neuroinflammation in EAE O. Rojas (Toronto, CA)

Single cell transcriptomics identifies multiple sclerosis-specific expression profiles ofcerebrospinal fluid cells

G. Meyer zu Hörste (Münster, DE)

Novel anti-neuronal antibodies in Multiple Sclerosis J.D.E. Parratt (Sydney, AU)

Concerted T Cell Response in Experimental autoimmune encephalomyelitis and Multiplesclerosis

N. Saligrama (Stanford, US)

A distinct repertoire of the γδ T cell population is associated with disease severity ofmultiple sclerosis

K. Shinoda (Fukuoka, JP)

Inflammatory mediators regulate ARNT2 expression in CNS and peripheral immunepopulations and influence their pathogenic or protective properties in MS and in models ofinflammatory neurodegeneration

J. Quandt (Vancouver, CA)

Cytotoxic CD4+CD28null T cell expansions are associated with worse disease progression inpatients with relapsing remitting multiple sclerosis

L.M. Peeters (Diepenbeek, BE)

Oxysterols impair IL-10 secretion and induces cholesterol accumulation in regulatory TR1cells via LXR signalling to favour autoimmunity

C. Pot (Lausanne, CH)

/ 97


PARP-1 deregulation in MS M. Meira (Basel, CH)

Protein Kinase CK2 Controls CD4+ T-cell Differentiation and is Critical for Pathogenicity inAutoimmune Neuroinflammation

E. Benveniste (Birmingham, US)

The lysosomal K+ channel KCNK6 correlates with upregulated T cell autophagy in MSpatients

F. Steffen (Mainz, DE)

Intrathecal oligoclonal bands synthesis: is it always a prognostic factor? J. Frau (Cagliari, IT)

Gut-Brain Axis: Deciphering the role of mucosal and systemic IgA in gut dysbiosisassociated with multiple sclerosis

A.-K. Pröbstel (San Francisco, US)

A bidirectional association between the gut microbiota and CNS disease in a progressivebisphasic murine model of multiple sclerosis

L. Kasper (Hanover, US)

CD4+ T cells from multiple sclerosis patients acquire regulatory characteristics followingexposure to a gut commensal-derived antigen

L. Kasper (Hanover, US)

Vitamin D Levels and MS Features in Progressive Multiple Sclerosis D. Ontaneda (Cleveland, US)

Impact of smoking on treatment response in multiple sclerosis patients receiving diseasemodifying therapies

J. Sequeira (Barcelona, ES)

Latent γHV-68 Infection Facilitates MS-like Symptoms through Memory B Cells in EAE A.C. Márquez (Vancouver, CA)

Synergistic effects of combined sodium chloride and saturated long chain fatty acidchallenge on differentiation of Th17 cells in neuroinflammation

A. Hammer (Erlangen, DE)

Fresh fish consumption is associated with a lower risk of multiple sclerosis independent ofserum 25OHD levels

A.M. Langer-Gould (Pasadena, US)

Short-term exposure to ambient air pollution and occurrence of multiple sclerosis relapses M. Jeanjean (Rennes, FR)

Different environmental stimuli may activate common biological processes potentiallyinvolved in multiple sclerosis

R. Mechelli (Rome, IT)

Post-vaccination autoimmune CNS demyelination in a family with MOG antibodies - Genes orenvironment?

A.-K. Pröbstel (Basel, CH)

/ 97


Salt-sensitive alterations in gut microbiota impact Th17 cells and neuroinflammation S. Jörg (Erlangen, DE)

Comparison of humoral immunity against acid-fast bacilli lipophilic antigens in patients withJapanese MS and NMOSD

K. Yokoyama (Tokyo, JP)

Smoking is associated with increased relapse rate in natalizumab-treated MS E.R. Petersen (Copenhagen, DK)

Vaccines increase the risk of relapses in neuromyelitis optica spectrum disorder amonguntreated patients

M.A. Mealy (Baltimore, US)

Gut dysbiosis is associated with disability progression in Spanish multiple sclerosis patients R. Del Campo (Madrid, ES)

Relevance of the microbiota during the autoimmune phase in a viral model of multiplesclerosis

L. Mestre (Madrid, ES)

Smoking on disability accumulation in Neuromyelitis Optica and Multiple Sclerosis S. Messina (Oxford, GB)

Rapid and efficient generation of human oligodendrocytes from induced pluripotent stemcells to model demyelinating diseases

L. Starost (Münster, DE)

Interleukin 17 affects hippocampal plasticity and cognition in multiple sclerosis M. Di Filippo (Perugia, IT)

Astrocytic Junctional Adhesion Molecule-A Promotes CNS Inflammatory Lesion Pathogenesis C. Chapouly (New York, US)

Proteomic analysis of CNS-derived MicroVescicles in the Cerebrospinal Fluid of MS M. Puthenparampil (Padua, IT)

MS as a transmissible protein misfolding disorder S. Tsutsui (Calgary, CA)

CD320-vitamin B12 links to MS thru S1P1 signaling in activated astrocytes J. Chun (La Jolla, US)

Demyelination controls epigenetic changes in multiple sclerosis hippocampus R. Dutta (Cleveland, US)

Longitudinal follow up of optical coherence tomography determined MS phenotypes withretinal and brain imaging

N. Gonzalez Caldito (Baltimore, US)

Serpina3n: potential biomarker in patients with progressive multiple sclerosis N. Fissolo (Barcelona, ES)

VEGF in cerebrospinal fluid from patients with RRMS, PPMS and ALS R. Dersch (Freiburg, DE)

/ 97


Leptomeningeal contrast enhancement in multiple sclerosis is associated with grey matteratrophy and higher disability

G. Makshakov (Saint-Petersburg, RU)

Human Stem Cell-based Screen for Small Molecules that Promote OligodendrocyteDifferentiation, Myelination, and Neuronal Survival

D.J. Zack (Baltimore, US)

Reconstruction of the pan-glial network during induced pluripotent stem cell-derivedremyelination process

S. Mozafari (Paris, FR)

Nodes of Ranvier reclustering can precede remyelination: a role in repair? M. Thetiot (Paris, FR)

Relationships between reorganization of functional brain network topology and cognition inclinically isolated syndrome: A 1 year Resting-state fMRI longitudinal study

I. Koubiyr (Bordeaux, FR)

The severity of functional and structural brain pathology reflects information processingspeed deficits in multiple sclerosis

K.A. Meijer (Amsterdam, NL)

Cortical lesions and their correlates in multiple sclerosis: findings from a large cohort at 7T C.A. Treaba (Charlestown, US)

Neuroinflammatory component of cerebellar pathology in multiple sclerosis by 11C-PBR28MR-PET

V. Barletta (Boston, US)

Preferential Spinal Cord Volume Loss in Primary Progressive Multiple Sclerosis C. Tsagkas (Basel, CH)

Dynamic functional network connectivity in CIS patients: A longitudinal study M. Hidalgo de la Cruz (Milan, IT)

Impact of removing facial features from MR images of MS patients on automatic lesion andatrophy metrics

A. de Sitter (Amsterdam, NL)

Impact of deep grey matter volume loss on neurological impairment in patients withmultiple sclerosis: a 6-year follow-up study with annual MRI

S. Magon (Basel, CH)

Whole brain magnetic resonance fingerprinting in multiple sclerosis S. Llufriu (Barcelona, ES)

Longitudinal structural network reorganisation in early relapsing-remitting MultipleSclerosis

V. Fleischer (Mainz, DE)

Multiple sclerosis patients who improve in their disability over time develop less brainatrophy compared to those who remain stable or progress

E. Ghione (Buffalo, US)

/ 97


Predicting clinical progression in multiple sclerosis six and twelve years after onset I. Dekker (Amsterdam, NL)

Improved visualization of cortical lesions in multiple sclerosis using MP2RAGE at 7T E.S. Beck (Bethesda, US)

Lesions with hyperintense rim on Quantitative Susceptibility Mapping demonstrate moreinflammation on PET-PK11195

U. Kaunzner (New York, US)

Pattern recognition for Neuroimaging Toolbox PRoNTo: a pilot study in predicting clinicallyisolated syndrome conversion

D. Pareto (Barcelona, ES)

Normative rates of healthy age-related brain volume changes as assessed by SIENA on alarge MRI dataset

M. Battaglini (Siena, IT)

Contrast enhanced Susceptibility-Weighted Imaging of Acute and Chronic MS lesions A. Gass (Mannheim, DE)

Within patient fluctuation of brain volume estimates from short-term repeated MRImeasurements using SIENA/FSL

R. Opfer (Hamburg, DE)

Quantitative MRI Texture Analysis of Enhancing and Non-enhancing T1-hypointense Lesionswithout Application of Contrast Agent in Multiple Sclerosis

S.M. Nabavi (Tehran, IR)

Age-dependent cut-off for pathological brain volume loss measured with SIENA/FSL R. Opfer (Hamburg, DE)

Associations Between Low Conscientiousness and Cognitive Impairment in MS May Be Dueto Shared Pathophysiology: Structural Network Disruption of Frontal Cortex Regions

T. Fuchs (Buffalo, US)

Altered subcortical sensorimotor integration in multiple sclerosis: a combinedneurophysiological and MRI study

C. Giannì (Rome, IT)

Dynamic volumetric changes of hippocampal subfields in CIS patients: a 2-year MRI study L. Cacciaguerra (Milan, IT)

Leptomeningeal enhancement on Gadolinium-enhanced 3D-FLAIR MRI in MS vs. non-MSpatients: demographic characteristics, and relationship to disease modifying therapy andwhite matter disease activity

D.S. Titelbaum (Brockton, US)

Defining a minimal meaningful lesion size in multiple sclerosis S. Grahl (Munich, DE)

Column-specific demyelination in Spinal Cord Normal Appearing White Matter occurring inMultiple Sclerosis: A preliminary study using inhomogeneous Magnetization Transfer andDiffusion Tensor Imaging

H. Rasoanandrianina (Marseille, FR)

/ 97


MRI myelin water fraction provides evidence of long-term neuro-recovery in alemtuzumabtreated multiple sclerosis patients

I.M. Vavasour (Vancouver, CA)

Lesion-based disruption of connections between the amygdala and surrounding ipsilateralstructures may be protective against fatigue in multiple sclerosis


Occurrence of diffusely abnormal white matter in individuals with clinically isolatedsyndromes suggestive of multiple sclerosis

C. Laule (Vancouver, CA)

Identification of new cortical lesions on longitudinal 7-Tesla MP2RAGE subtraction MRI inmultiple sclerosis

D. Harrison (Baltimore, US)

Application of Neurite Orientation Dispersion and Density Imaging (NODDI) in clinicallyisolated syndrome (CIS)

S. Collorone (London, GB)

The impact of CNS inflammation on the GABAergic system: A Multi-ligand PET study utilizing[11C] Flumazenil and [11C] PK11195

Y. Kang (New York, US)

Cortical Mantle Thinning in the Visual Cortex in Pediatric-Onset Multiple Sclerosis R. Datta (Philadelphia, US)

Coordinate based random effect size meta-analysis shows regions of GM atrophy do notdevelop independently in MS and CIS

C. Tench (Nottingham, GB)

Longitudinal study to measure iron deposit in basal ganglia and related structures inpatients with clinically isolated syndrome


Evolution of venous narrowing in acute MS lesions A. Gass (Mannheim, DE)

Normative data of MRI-derived thalamic volumes from a large dataset of healthy subjects G. Gentile (Siena, IT)

Spinal cord ring enhancement patterns in neuromyelitis optica spectrum disorder:comparison with multiple sclerosis

Y.-M. Lim (Seoul, KR)

Myelin Deterioration Occurs in Relapsing Remitting Multiple Sclerosis Patients MeetingCriteria for “No Evidence of Disease Activity”

A. Harel (New York, US)

Resting state fMRI and graph theory for the automatic classification of relapsing remittingMultiple Sclerosis with different disease duration

G. Castellazzi (Pavia, IT)

/ 97


3T FLAIR* MRI improve the differentiation between multiple sclerosis and CNS vasculitiswhite matter lesions

P. Maggi (Bruxelles, BE)

Mapping neuroeconomic decisions in multiple sclerosis: a connectivity approach S. Llufriu (Barcelona, ES)

Probing Myelin and Axonal Integrity in Multiple Sclerosis Brains G. Franco (Nashville, US)

Comparative study of brain atrophy measures in CIS and MS patients: preliminary results ofa cross-sectional analysis

S. Cappelle (Barcelona, ES)

Altered cerebellar functional connectivity is associated to clinical disability in multiplesclerosis

S. Tommasin (Rome, IT)

Independent component analysis of cerebral blood flow reveals MS-specific spatial patternsassociated with clinical disability

N. Bergsland (Buffalo, US)

Microstructural alterations precede subcortical deep grey matter volume loss in patientswith clinically isolated syndrome

I. Koubiyr (Bordeaux, FR)

Characterization of spinal cord pathology and its correlates at ultra-high field MRI R. Ouellette (Charlestown, US)

Distinct associations of cross-sectional spinal cord areas with clinical disability in Japanesepatients with multiple sclerosis and neuromyelitis optica spectrum disorder withaquaporin-4-IgG

Y. Nakamura (Fukuoka, JP)

Regional patterns of brain atrophy development in pediatric and adult multiple sclerosispatients: a 3.5 year study

E. De Meo (Milan, IT)

Regional brain atrophy differences and relationship to disability in NMOSD and MS E. Russell (Vancouver, CA)

Longitudinal characterization of MRI phenotypes based on cerebral lesions and atrophy inmultiple sclerosis: a five year study

C. Hemond (Boston, US)

A semi-automatic method to segment multiple sclerosis lesions on FLAIR magneticresonance images

L. Storelli (Milan, IT)

Trans-synaptic neurodegeneration 12 months following optic neuritis - a longitudinal OCTand DTI study

J.B. McKee (Headington, GB)

Characterization of the haemodynamic response function in multiple sclerosis A.A. Alahmadi (London, GB)

/ 97


Metabolic substrates of efficiency reduction in the frontoparietal network in multiplesclerosis

E. Solana (Barcelona, ES)

Reduced dynamism of functional connectivity is associated with cognitive impairment in MSpatients: a dynamic functional connectivity study in a multi-center setting

A. d'Ambrosio (Milan, IT)

Do multiple sclerosis lesions affect automatic brain structure segmentation? X. Llado (Girona, ES)

Presence of focal and diffuse cervical cord tissue damage in early relapsing-remitting MS: Amagnetization transfer study

A. Kerbrat (Rennes, FR)

Accelerated thalamic atrophy occurs following acute optic neuritis E.S. Sotirchos (Baltimore, US)

The relationship between network measures and magnetic resonance imaging metrics inmultiple sclerosis

T. Charalambous (London, GB)

Automated Detection of Central Vein Sign in White Matter Lesions for the Diagnosis of MS J.D. Dworkin (Philadelphia, US)

Statistical Separation of Spatially Confluent but Temporally Distinct White Matter Lesions J.D. Dworkin (Philadelphia, US)

Shrinking of T2-hyperintense white matter lesions in early multiple sclerosis V. Biberacher (München, DE)

Evidence for progressive neurodegeneration in the cervical cord of patients with earlyprimary progressive MS during 3-year follow-up

R. Cortese (London, GB)

Cervical spinal cord volume and diffuse spinal cord abnormalities distinguish multiplesclerosis patients with different levels of disability already 5 years after disease onset

M. Andelova (Prague, CZ)

Structure and function of the corticospinal tract and motor cortex in multiple sclerosis J.Y. Garber (Sydney, AU)

Individual profiles of microglial activation drive the progression of clinical disability in MS B. Bodini (Paris, FR)

Phase 1 safety study of ferumoxytol, an ultrasmall superparamagnetic iron oxidenanoparticle, in multiple sclerosis and healthy volunteers at 7-tesla

M.K. Schindler (Bethesda, US)

Sources of Variability in Brain Atrophy Measurements in Individual MS Patients A. Tsang (Cambridge, US)

Automated, Modular MRI Processing for Multiple Sclerosis using the BRAINMAP Framework B.E. Dewey (Baltimore, US)

/ 97


Grey matter connectivity in clinically isolated syndromes D. Pareto (Barcelona, ES)

Improving the accuracy of brain tissue loss assessment in patients with multiple sclerosis: arole for diffusion imaging?

C. Wang (Sydney, AU)

Investigating resting-state BOLD variability in early Multiple Sclerosis G. Bommarito (Genoa, IT)

Validation of fully automated machine-learning algorithm for T2 lesion segmentation fromclinical MRI in multiple sclerosis

J.J. Feng (Cleveland, US)

Comparison between the 2010 McDonald and 2016 MAGNIMS MRI criteria for disseminationin space in patients with a clinically isolated syndrome. Does the recent recommendationregarding the current criteria improve diagnostic accuracy?

R. Lamas Pérez (Sevilla, ES)

Increased between-network functional connectivity as a compensatory mechanism tomaintain walking ability in MS patients

S. Ruggieri (Rome, IT)

Larger maximal lifetime brain growth is associated with faster motor speed in earlyrelapsing multiple sclerosis

C. Riley (New York, US)

Dark rims around white matter lesions using Gray-Matter Double-Inversion-Recovery MRI: Anovel specific imaging marker for Multiple Sclerosis

J.-M. Tillema (Rochester, US)

Structural MRI correlates of hand motor performance in patients with multiple sclerosis C. Cordani (Milan, IT)

Retinal inner nuclear layer volume; a potential new outcome measure for optic neuritistreatment trials in MS

L.J. Balk (Amsterdam, NL)

Visual evoked potentials are more sensitive than optical coherence tomography in clinicallyisolated syndrome

L. Leocani (Milan, IT)

Silent retinal atrophy in multiple sclerosis is mainly due to silent optic nerve lesions O. Outteryck (Lille, FR)

Association of retinal layer architecture and the development of neuropsychological deficitsin early multiple sclerosis

C. Wetzlmair (Munich, DE)

A multidisciplinary assessment through OCT and correlations to brain pathology andendothelial factors in multiple sclerosis

R. Lanzillo (Naples, IT)

/ 97


Examining cross-sectional relationships of optical coherence tomography, cervical cord MRIand disability in secondary progressive MS

F. De Angelis (London, GB)

Retinal changes in aquaporin-4 antibody seropositive Neuromyelitis Optica SpectrumDisorders: a longitudinal study

F.C. Oertel (Berlin, DE)

Spectrum of stiff person syndrome expands with presence of retinal pathology T. Shoemaker (Baltimore, US)

Retinal ganglion cell layer thickness predicts disease activity in clinically isolated syndrome H.G. Zimmermann (Berlin, DE)

Optical Coherence Tomography as a Marker of Disease Severity and Disability in PediatricMultiple Sclerosis

N.M. Shukla (Houston, US)

An Investigation into the Relationship between Optical Coherence Tomography (OCT) andCognitive Fatigue in People with Multiple Sclerosis


Cognitive impairment as prognostic factor in pediatric and juvenile multiple sclerosis R. Lanzillo (Naples, IT)

Neurophysiological measures of fatigue in multiple sclerosis S.S. Ayache (Créteil, FR)

The triple stimulation technique: a potential surrogate marker for motor axonal loss inmultiple sclerosis

X. Giffroy (Esneux, BE)

Fatigue in multiple sclerosis:Is it related to cytokines and hypothalamic-puituitary-adrenalaxis?

A. Akcali (Gaziantep, TR)

Cognitive impairment in Multiple Sclerosis is associated with slowing of resting stateoscillatory activity on magnetoencephalography

E.M. Strijbis (Amsterdam, NL)

Chronic 4-aminopyridine treatment enhances intracortical glutamatergic transmission inprogressive multiple sclerosis

S. Gelibter (Milan, IT)

Are We Underestimating the Severity of Cognitive Dysfunction in MS? M. Weber (Cleveland, US)

Gray matter atrophy and microstructural white matter abnormalities underlying cognitiveimpairment in benign MS

M.A. Rocca (Milan, IT)

Cognitive impairment in Multiple Sclerosis: the contribution of cognitive reserve andregional gray matter volumes

A. Bisecco (Napoli, IT)

/ 97


Neuroticism is linked to smaller hippocampal volume and worse memory in early multiplesclerosis

V.M. Leavitt (New York, US)

Dissociable Neural Correlates of Speed and Memory in Early Multiple Sclerosis: A LatentVariable Approach

J.F. Sumowski (New York, US)

Evolution of cognitive function in MS and its relationship to physical disability and MRImetrics

D. Pinter (Graz, AT)

Basal Ganglia structural and functional abnormalities in Multiple Sclerosis are related tocognitive impairment

Á.J. Cruz-Gómez (Castellón de la Plana, ES)

Cognitive status of patients with Multiple Sclerosis is associated to cognitive reserve betterthan conventional MRI measures

A. Gallo (Naples, IT)

Intensive neurorehabilitation is associated with improved fatigue and depression inpatients with progressive MS

M. Congiu (Milan, IT)

Specific rehabilitation improves information processing speed and attention in MS: arandomized trial against non-specific training with semi-ecological evaluation

D. Lamargue-Hamel (Bordeaux, FR)

Problem solving in patients with Multiple Sclerosis – Analysing information and optimisingstrategies under different conditions

K. Zebenholzer (Vienna, AT)

The Symbol Digit Modalities Test and the Frontal Systems Behaviour Scale: A one-yearfollow-up study

L. Querol (Barcelona, ES)

Neuropsychological and anatomical correlates of theory of mind in patients with multiplesclerosis

M.A. Chalah (Créteil, FR)

Evidence for flattened emotional experience in patients with clinically isolated syndromeand early multiple sclerosis

F. Paul (Berlin, DE)

Cerebrospinal fluid neurofilament light chain is a marker of disease activity in multiplesclerosis

E. Poletto (Verona, IT)

Autoantibodies to Neurofilament light protein as a potential Biomarker of treatmentresponse and disease progression in Multiple sclerosis

F. Puentes (London, GB)

Differential gene expression in stable and active MS patients treated with fingolimod H. Bach Søndergaard (Copenhagen, DK)

/ 97


Anticipation of long-term disability progression in PPMS using MRI: a 15-year longitudinalstudy

M.A. Rocca (Milan, IT)

Serum Neurofilament Light Levels at the Time of a Clinically Isolated Syndrome areAssociated with Long-Term Clinical and Radiological Outcome

T. Plavina (Cambridge, US)

High neurofilament light chain levels in CSF are associated with CDMS diagnosis in childrenand adults with CIS

R.M. van der Vuurst de Vries (Rotterdam, NL)

Serum glial fibrillary acidic protein correlates with disease severity and neuroaxonal demisein multiple sclerosis; a pilot study using Simoa technology

A. Abdelhak (Ulm, DE)

Relationship between different cerebrospinal fluid biomarkers in multiple sclerosis:meaning and use in clinical practice

B. Casanova (València, ES)

Lower baseline levels of vitamin D are associated with a higher risk of new lesiondevelopment in patients with relapsing multiple sclerosis

G.J. Opiteck (San Diego, US)

Neuroinflammation and neuroaxonal damage in multiple sclerosis: a cross-sectionalcerebrospinal fluid-based proteomic study

L. Gaetani (Perugia, IT)

Neurofilament light chain in CSF and serum in relation to disease activity and brain volumeloss during four years of follow-up in a cohort of patients with CIS and RRMS

I. Håkansson (Linköping, SE)

Serum Neurofilament light chain correlates with disease activity and predicts clinical andMRI outcomes in MS

C. Barro (Basel, CH)

Neurofilament light chain in human blood is a predictor of disease worsening in relapsing-remitting multiple sclerosis

J. Kuhle (Basel, CH)

Intrathecal B-cell inflammation influences CSF macrophage activity and the degree ofcortical pathology in multiple sclerosis

R. Magliozzi (Verona, IT)

MS treatment effects on plasma cytokine receptor levels S.K. Bedri (Stockholm, SE)

Serum neurofilament light chain as a biomarker for acute and chronic neuronal damage inearly relapsing-remitting multiple sclerosis

N. Siller (Mainz, DE)

Baseline cerebellar volume predicts subsequent clinical disability in Multiple Sclerosis: MRIFindings from the CombiRx trial

M. Petracca (New York, US)

/ 97


Serum exosomes expression of myelin proteins is a biomarker of the multiple sclerosisactivity

M.P. Mycko (Lodz, PL)

Intrathecal immunoglobulin synthesis as a predictive marker for disability progression inmultiple sclerosis

C. Gasperi (Munich, DE)

Decreased cerebrospinal fluid antioxidative capacity is associated with disease severity andprogression in early multiple sclerosis

M.M. Voortman (Graz, AT)

Change of olfactory function as a marker of inflammatory activity and disability progressionin MS

G. Bsteh (Innsbruck, AT)

Multiple sclerosis: structure-function correlations in the cerebral cortex H. Beadnall (Sydney, AU)

Conduction velocity in demyelinated cerebral white matter: a structure-function correlationstudy in optic radiation

C. Wang (Sydney, AU)

Elucidation of pro-resolving lipid mediators in the cerebrospinal fluid: implications formultiple sclerosis pathogenesis

G. Kooij (Amsterdam, NL)

Single-Cell mRNA Marker Analysis Reveals Appearance of t-SNE-Defined New B-Cell Clustersin Cynomolgus Monkeys in Response to Ofatumumab Treatment

P. Couttet (Basel, CH)

The neutrophil-to-lymphocyte ratio is associated with multiple sclerosis I.C. Hasselbalch (Copenhagen, DK)

Delayed-release dimethyl fumarate demonstrated no evidence of difference in clinicaloutcomes vs fingolimod in patients with RRMS: a propensity-matched comparativeeffectiveness analysis of the German NeuroTransData registry

S. Braune (Prien, DE)

Sustained disease remission in multiple sclerosis after autologous haematopoietic stem celltransplantation. The Italian experience

G. Boffa (Genova, IT)

Naturally or induced Immunization against CCL20 confer protection against experimentalautoimmune encephalomyelitis

A. Karni (Tel Aviv, IL)

Ocrelizumab reduces disability progression independent of relapse activity in patients withrelapsing multiple sclerosis

L. Kappos (Basel, CH)

Long-Term Lymphocyte Counts in Patients with Relapsing-Remitting Multiple Sclerosis(RRMS) Treated with Cladribine Tablets 3.5 mg/kg: Total Lymphocytes, B and T Cell Subsets

P. Soelberg-Sorensen (Copenhagen, DK)

/ 97


Characterization of the efficacy of ORY-2001, a novel epigenetic drug for the treatment ofmultiple sclerosis, during the effector phase of the EAE model

T. Maes (Cornella de Ll., ES)

Subcutaneous Low Dose Ofatumumab in Cynomolgus Monkeys Induced Changes inLymphocyte Subsets and Reversible Cytoarchitectural changes in Lymph Nodes

D. Theil (Basel, CH)

Rescue therapy with propionic acid reverts the pro-inflammatory effects of a high-fat-diet inneuroinflammation

J. Mäurer (Erlangen, DE)

Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a smallsubset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummyinterferon beta-1a-controlled study

H.-C. von Buedingen (Basel, CH)

Dimethyl fumarate reduces the frequency of antigen-experienced B cells in patients withmultiple sclerosis

R.H. Hansen (Copenhagen, DK)

Efficacy of Delayed-release Dimethyl Fumarate in Newly Diagnosed Patients With Relapsing-Remitting Multiple Sclerosis: Eight-Year Follow-up of an Integrated Analysis of DEFINE,CONFIRM, and ENDORSE

R. Gold (Bochum, DE)

Peginterferon Beta-1a Improves Clinical and Radiological Disease Outcomes in Patients WhoAre Newly Diagnosed with Relapsing Multiple Sclerosis: Subgroup Analysis of ADVANCE

S.D. Newsome (Baltimore, US)

Comparative effectiveness and discontinuation of dimethyl fumarate and fingolimod in twolarge academic medical centers at 24-month follow-up

C.M. Hersh (Las Vegas, US)

Real Life Use of natalizumab and fingolimod - Data from the nation-wide Austrian MultipleSclerosis Treatment Registry

M. Guger (Linz, AT)

Dimethyl fumarate vs. fingolimod in multiple sclerosis: an independent, multi-centre, realworld, quasi-randomized study

L. Prosperini (Rome, IT)

Rates of Lymphopenia Year-by-year in Patients with Relapsing Multiple Sclerosis Treatedand Retreated with Cladribine Tablets 3.5mg/kg

S. Cook (Newark, US)

Effects of Cladribine Tablets on CD4+ T Cell Subsets in the ORACLE-MS Study: Results froman Analysis of Lymphocyte Surface Markers

O. Stuve (Dallas, US)

T-cell population changes and serious infection rates in the controlled periods of the pivotalphase III trials of ocrelizumab in multiple sclerosis

P. Vermersch (Lille, FR)

/ 97


Two years real life safety, tolerability and efficacy of Dimethyl fumarate in an Italianmulticentre study

G. Mallucci (Pavia, IT)

Rituximab real life efficacy in MS: an observational multicentre study S. Malucchi (Orbassano, IT)

Slowing of Cortical Grey Matter Atrophy With Teriflunomide is Associated With DelayedConversion to Clinically Definite MS

R. Zivadinov (Buffalo, US)

Confirmed Disability Improvement in Patients Treated with Fingolimod in Phase 3 andExtension Trial Programmes for up to 96 Months

B.A. Cree (San Francisco, US)

Comparison of rituximab and highly effective second line disease modifying therapies afterbreakthrough disease activity in relapsing-remitting multiple sclerosis

J. Salzer (Umeå, SE)

Relapse rates and disability in the modern treatment era of neuromyelitis optica: Data froma specialist UK centre

D.H. Whittam (Liverpool, GB)

Design of a Phase II Dose Range Finding, Efficacy and Safety Study of the Bruton’s TyrosineKinase Inhibitor Evobrutinib (M2951) in Relapsing Multiple Sclerosis Patients

X. Montalban (Barcelona, ES)

Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing andprimary progressive multiple sclerosis

S. Hauser (San Francisco, US)

Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remittingmultiple sclerosis: a comparative longitudinal study

T. Kalincik (Melbourne, AU)

T cell mediated experimental CNS autoimmunity induced by PLP in SJL mice is modulated byEvobrutinib (M2951) a novel Bruton’s tyrosine kinase inhibitor

U. Boschert (Billerica, US)

Real world efficacy and safety of teriflunomide in patients with relapsing-remitting multiplesclerosis

C. Boz (Trabzon, TR)

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis in clinical practice at 24-month follow-up

C.M. Hersh (Las Vegas, US)

An Observational Study of Alemtuzumab-treated Relapsing MS Patients at the UBC MS Clinic H.Y. Yong (Vancouver, CA)

Safety, Tolerability, and Pharmacodynamics of Intravenous and Subcutaneous Doses of theAnti-CD52 Antibody GLD52 in Patients With Progressive MS: A Randomised, Controlled,Single Ascending Dose Trial

D.H. Margolin (Cambridge, US)

/ 97


Dimethyl Fumarate therapy is associated with immune-deviation and anti-inflammatorycytokine profiles in B and T cells in patients with Multiple Sclerosis

E. Najjar (Haifa, IL)

Changing Disease Modifying Therapy Switching Dynamics for Relapsing-Remitting MultipleSclerosis Patients

C. Wakeford (Cambridge, US)

Evaluation of the Long-term Treatment Effect of Teriflunomide on Cognitive Outcomes andAssociation With Brain Volume Change: Data From TEMSO and its Extension Study

T. Sprenger (Basel, CH)

Incidence rates of malignancies in patients with multiple sclerosis in clinical trials andepidemiological studies

S. Hauser (San Francisco, US)

Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosiswho received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA IIstudies

C. Papeix (Paris, FR)

Subgroup analyses of no evidence of disease activity in patients with relapsing multiplesclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I andOPERA II studies

B. Turner (London, GB)

Efficacy and safety of alemtuzumab versus fingolimod in RRMS patients after switch fromnatalizumab: a retrospective analysis

S. Pfeuffer (Münster, DE)

Cladribine Tablets Produce Selective and Discontinuous Reduction of B and T Lymphocytesand Natural Killer Cells in Patients with Early and Relapsing Multiple Sclerosis (ORACLE-MS,CLARITY and CLARITY Extension)

O. Stuve (Dallas, US)

A central role of B cells in MS control and causing autoimmunity after alemtuzumab D. Baker (London, GB)

Monomethyl fumarate treatment impairs maturation of human myeloid dendritic cells andtheir ability to activate T cells

M.A. Mazzola (Boston, US)

Effect of ocrelizumab on B and T cell immune repertoires in patients with relapsing multiplesclerosis

S. Laurent (San Francisco, US)

The immune receptor expression pattern in peripheral-blood associated with JCVseropositivity in patients with multiple sclerosis is not affected by natalizumab

A. Harrer (Salzburg, AT)

Achievement of No Evidence of Disease Activity with Daclizumab Beta Versus IntramuscularInterferon Beta-1a Treatment Across Patient Subgroups in DECIDE


/ 97


Immunosuppressive potential of human Wharton jelly mesenchymal stem cells in multiplesclerosis patients

M. Swiderek-Matysiak (Lodz, PL)

“Real-life” outcomes in a monocentric cohort of highly active Multiple Sclerosis patientstreated with Alemtuzumab

L. Moiola (Milan, IT)

Efficacy and safety of generic glatiramer acetate Timexon®: results of the 12-monthextension of BCD-063-1 international double-blind randomized placebo-controlled clinicalstudy of efficacy and safety of Timexon® in comparison with Copaxone®

C. Tursunova (Saint-Petersburg, RU)

Secukinumab in Relapsing Multiple Sclerosis: experience in two cases with concomitantankylosing spondylitis

R. Robles Cedeño (Girona, ES)

A cost-effectiveness analysis using real-world data from the MSBase Registry: comparingnatalizumab to fingolimod in patients with inadequate response to disease modifyingtherapies in relapsing-remitting multiple sclerosis in Scotland

C. Acosta (Zug, CH)

Teriflunomide: immunomodulatory effect on adaptive and innate immune cell subsets I. Gandoglia (Genoa, IT)

Fingolimod induces BAFF and expands circulating transitional B cells without activatingmemory B cells and plasma cells in multiple sclerosis

Y. Miyazaki (Sapporo, JP)

Induction of Disease Remission With One Cycle of Alemtuzumab in Relapsing RemittingMultiple Sclerosis

D.E. Klein (Middletown, US)

Real-life experience with rituximab for the treatment of multiple sclerosis: report from twoMS referral centres

F.C. Pérez Miralles (Valencia, ES)

Ozanimod does not impact cytotoxic T lymphocyte function in vitro demonstratingdifferentiation from fingolimod’s activity on SET-PP2A

D. Guimond (San Diego, US)

In Vitro Data Reveals Potential Novel Mechanism of Action of Teriflunomide on CNSMicroglia and Astrocytes

A. Edling (Framingham, US)

Teriflunomide Use in European Clinical Practice in Patients With Relapsing Forms of MultipleSclerosis: An Overview of Regional Real-World Studies

A. Chan (Bern, CH)

EVOLVE-MS-2: A randomized, double-blind, phase 3 study of the gastrointestinal tolerabilityof ALKS 8700 versus dimethyl fumarate in relapsing-remitting multiple sclerosis

R.T. Naismith (Saint Louis, US)

Spanish Registry of patients with multiple sclerosis treated with fingolimod (GILENYARegistry): safety and effectiveness after four years of registry

J. Meca-Lallana (Murcia, ES)

/ 97


An update on pregnancy outcomes following ocrelizumab treatment in patients withmultiple sclerosis and other autoimmune diseases

S. Vukusic (Lyon, FR)

Sustained modifications of subsets and capacities of cytokine production of B cells underinterferon-β in multiple sclerosis

T. Guerrier (Lille, FR)

Rituximab in multiple sclerosis; Frequency and clinical relevance of anti-rituximab drugantibodies

A. Juto (Stockholm, SE)

Once Daily Oral CHS-131, a Novel PPARγ Agonist, Reduces Both Neuroinflammation andGray Matter Volume Depletion in Patients with Relapsing-Remitting Multiple Sclerosis: aRandomized, Placebo Controlled Double-blind, Phase 2b, Multicenter Study

D. Weinstein (Redwood City, US)

Investigating Neuroprotective Effects of Phenytoin on Optic Nerve Magnetization TransferRatio (MTR) in Acute Optic Neuritis

A.T. Toosy (London, GB)

Dimethyl fumarate (DMF) improves behavioral outcomes in a mouse model of progressivemultiple sclerosis

B. Bai (Cleveland, US)

Patterns of regional gray matter and white matter atrophy in patients starting fingolimod ornatalizumab: a 2-year tensor-based morphometry study

P. Preziosa (Milan, IT)

Blocking LINGO Family Promotes Axon Regeneration in the Optic Nerve Crush Model S. Mi (Cambridge, US)

Predictors of an Opicinumab Treatment Effect and Identification of an EfficacySubpopulation: A Post hoc Analysis of the SYNERGY Study

S. Sheikh (Cambridge, US)

Keeping mitochondria on the road: Teriflunomide maintains mitochondrial motility levels inaxons challenged with oxidative stress

E. Bros (Berlin, DE)

Selective Estrogen Receptor Modulators Significantly Enhance Remyelination in an EstrogenReceptor-Independent Manner


Phase I/II clinical trials testing multiple dosing of intrathecal mesenchymal stem cell-derived neural progenitors in patients with progressive multiple sclerosis

S.A. Sadiq (New York, US)

Fingolimod-mediated axonal protection during demyelination facilitates myelin increaseduring recovery

B. Bai (Cleveland, US)

Protection of mitochondrial function by dimethyl fumarate in an animal model of multiplesclerosis

D. Schiza (London, GB)

/ 97


Alemtuzumab Reduced MRI Lesions and Slowed Brain Volume Loss in CARE-MS II PatientsSwitching From SC IFNB-1a: 5-Year Follow-up After Alemtuzumab (TOPAZ Study)

D. Pelletier (Los Angeles, US)

Predictors of relapses and disability progression after stopping disease-modifying therapiesfor multiple sclerosis

I. Kister (New York, US)

Alemtuzumab after Natalizumab SWitch in Evolving Rapidly Severe Multiple Sclerosis(ANSWERS MS)

P.J. Gallagher (Glasgow, GB)

Efficacy of a Third Course of Alemtuzumab in Patients With Active Relapsing-RemittingMultiple Sclerosis Who Experienced Disease Activity After the Initial Two Courses: PooledAnalysis of CARE-MS I and II

A. Traboulsee (Vancouver, CA)

Alemtuzumab Decreased MRI Disease Activity and Slowed Brain Volume Loss Over 5 YearsAfter Switching From SC IFNB-1a: Follow-up of CARE-MS I (TOPAZ Study)


Subcutaneous Interferon Beta-1a, 10-Year Results from the United Kingdom MultipleSclerosis Risk Sharing Scheme

G. Harty (London, GB)

Effectiveness, health outcomes and cost-effectiveness of first generation disease-modifyingdrugs in relapsing-onset multiple sclerosis: Nova Scotia evidence 1979-2010

M.G. Brown (Halifax, CA)

Sustained Efficacy of Daclizumab Beta Over up to 6 Years of Treatment and Improvementsin Efficacy Outcomes in Relapsing MS Patients who Switched From Intramuscular InterferonBeta-1a to Daclizumab Beta: Interim Results From EXTEND


Disease modifying therapy improves disability outcomes in relapsing-remitting multiplesclerosis over 22 years


Clinical outcomes were better for patients who remained on natalizumab compared to thosewho switched to oral or injectable therapies after 2 years in the TYSABRI ObservationalProgram

H. Butzkueven (Melbourne, AU)

Less frequent retreatment of rituximab is sufficient to maintain remission of neuromyelitisoptica spectrum disorder after long-term treatment of rituximab

H.J. Kim (Goyang, KR)

A Swedish Nationwide Pharmaco-Epidemiological Study of the Long-Term Safety andEffectiveness of Natalizumab (IMSE 1)

S. Kågström (Stockholm, SE)

Durable Improvements in Clinical Outcomes With Alemtuzumab in Patients With ActiveRRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS II Patients(TOPAZ Study)

B. Singer (St. Louis, US)

/ 97


Lateral ventricular volume as a proxy for brain volume loss in the assessment of noevidence of disease activity: results from a longitudinal, multicentre, real-world study


Big Multiple Sclerosis Data network: data sharing among five large MS registries P. Iaffaldano (Bari, IT)

Serum neurofilament light chain levels are increased at the onset of PML in natalizumabtreated MS patients

G. Dalla Costa (Milan, IT)

Improved Precision of Automatic Brain Volume Measurements in Patients with ClinicallyIsolated Syndrome and Multiple Sclerosis using Edema Correction

M. Warntjes (Linköping, SE)

Patients With Active RRMS Experience Durable Reductions in MRI Disease Activity andSlowing of Brain Volume Loss With Alemtuzumab: 7-Year Follow-up of CARE-MS II Patients(TOPAZ Study)

D. Pelletier (Los Angeles, US)

Effect of Teriflunomide on Lymphocyte Counts and Infections Over the Long-term in thePooled TEMSO and TOWER Extension Studies

G. Comi (Milan, IT)

Lymphocyte Decline and Reconstitution after Discontinuation in Patients with Severe,Prolonged Lymphopenia Treated with Delayed-release Dimethyl Fumarate

R.J. Fox (Cleveland, US)

Outcomes of Discontinuing Disease Modifying Therapy in Patients with Multiple SclerosisOver Age 60

L.H. Hua (Las Vegas, US)

5 years effectiveness of fingolimod in daily clinical practice: results of the non-interventional study PANGAEA

C. Cornelissen (Nürnberg, DE)

Characteristics of real-world disability improvement in relapsing-remitting multiplesclerosis patients treated with natalizumab in the TYSABRI® Observational Program

H. Wiendl (Münster, DE)

Comparative effectiveness of first line treatment strategies for multiple sclerosis M. Granqvist (Solna, SE)

A Swedish Nationwide Pharmaco-Epidemiological Study of the Long-Term Safety andEffectiveness of Fingolimod (IMSE 2)

Å. Leandersson (Stockholm, SE)

Pregnancy Outcomes in Patients With RRMS Treated With Alemtuzumab From the ClinicalDevelopment Program

D. Rog (Manchester, GB)

Breakthrough disease under high-dose biotin treatment in progressive multiple sclerosis F. Granella (Parma, IT)

/ 97


The ultrasensitive JCV DNA Tri-Plex qPCR* detects JCV specific genomic sequences in Tprotein, distinguishes pathogenic from non-pathogenic variants using the NCCR (Non-Coding Control Region) and identifies the virion capsid protein gene (VP1)

E.O. Major (Besthesda, US)

Pregnancy planning and outcome in MS patients after Mitoxantrone therapy J. Frau (Cagliari, IT)

Does IgG level impact JC virus index value? H. Zéphir (Lille, FR)

Risk of positive JC virus seroconversion in natalizumab treated patients decreases after 12months and increases with exposure to high dose methylprednisolone

C. Dwyer (Parkville, AU)

Cardiac safety of ozanimod in a QT/QTc trial and a phase 2 trial in RMS G. Comi (Milan, IT)

Patient initiation of fingolimod treatment: comparison of cardiac monitoring in-clinic and inthe Gilenya@Home program

J. Osborne (Grapevine, US)

Point of No Return: Outcomes from Acute Relapses of Neuromyelitis Optica Depend onSeverity

M. Levy (Baltimore, US)

First reported case of Aquired Hemophilia A (AHA) as secondary autoimmune diseasefollowing alemtuzumab treatment in multiple sclerosis


Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumabdiscontinuation in patients with multiple sclerosis?

J. Krämer (Münster, DE)

Safety of Alemtuzumab for Multiple Sclerosis After Exposure to Chemotherapeutic Agentsfor Patients with Multiple Sclerosis - Experience of a single MS center

D.A. Pimentel Maldonado (Worcester, US)

How best to communicate clinical trial information about DMD risks and benefits to MSpatients?

G. Reen (Egham, GB)

Alopecia totalis following alemtuzumab treatment in relapsing-remitting multiple sclerosis J. Zimmermann (Bonn, DE)

Third Japanese case of fingolimod-associated PML in natalizumab-naïve MS: Coincidence oralarm bell?

J. Nakahara (Tokyo, JP)

Ozanimod has an Improved Nonclinical Safety Profile Relative to Fingolimod S. Meier-Davis (San Diego, US)

First dose effects of fingolimod: Final results of an in-depth ECG and Holter study in 6,998German RRMS patients

V. Limmroth (Köln, DE)

/ 97


Pregnancy Outcomes in Patients With Multiple Sclerosis and Exposure to BrandedGlatiramer Acetate During All Three Trimesters

O. Neudorfer (Petach Tikva, IL)

Characterizing the Cytokine Profile Before and After antiCD20 Infusions: A Comparison ofRituximab Versus Ocrelizumab

E. Alvarez (Aurora, US)

Evaluation of a protocol to improve DMD risk and benefit understanding in MS patients: Arandomised crossover trial

G. Reen (Egham, GB)

An application of a novel statistical approach to predict patient-specific treatmentresponses to DMTs based on a continuous score

F. Bovis (Genova, IT)

Minimal or No Evidence of Disease Activity: which target to prevent long-term disability inmultiple sclerosis?

L. Prosperini (Rome, IT)

Disease Activity as Assessed by the MAGNIMS Score Predicts Long-Term Clinical DiseaseActivity Free Status and Disability Progression in Patients Treated with SubcutaneousInterferon Beta-1a

M.P. Sormani (Genoa, IT)

Defining areas of cognitive impairment in relapsing-remitting multiple sclerosis (RRMS) –baseline analysis of a longitudinal multicenter study in 15 German practice centers

M. Stumpfe (Berg, DE)

Long-term Disease Outcomes in Multiple Sclerosis Patients Categorised by Baseline BrainVolume and with No Disease Activity over 2 Years

M.H. Barnett (Sydney, AU)

Comparison between central and whole brain atrophy in multiple sclerosis measured byStructural Image Evaluation using Normalization of Atrophy (SIENA)

T. Sinnecker (Basel, CH)

Association of brain volume loss and NEDA outcomes in patients with relapsing multiplesclerosis in the OPERA I and OPERA II studies


Permeability of the blood-brain barrier predicts no evidence of disease activity at two yearsafter natalizumab or fingolimod treatment in relapsing-remitting multiple sclerosis

S.P. Cramer (Glostrup, DK)

Patient Reported Disease Modifying Therapy Adherence in the Clinic: A Reliable Metric? D.S. Conway (Cleveland, US)

Overall Response Score: A Novel Disability Endpoint That Allows for the IntegratedAssessment of Improvement and Worsening over Time in Patients with MS

I. Chang (Cambridge, US)

The effect of Dimethyl fumarate treatment on hippocampal metabolite levels in RRMS using1H-MR spectroscopy

K.A. Ribbons (New Lambton, AU)

/ 97


Silent lesions on MRI – Shifting goal post for treatment decisions in MS M. Min (Newcastle, AU)

Consensus statement on the use of gadolinium for magnetic resonance imaging used in thediagnosis and follow-up of patients with multiple sclerosis


A comparative-effectiveness analysis applying a 3 way propensity matching to real-worlddata from MSBase Registry in preparation for a cost effectiveness model: Patients switchingwithin firstline agents or to Natalizumab or Fingolimod in active RRMS


Efficacy of Siponimod on Disability Progression in SPMS Patients With and Without On-Study Relapses


Anti-inflammatory disease modifying treatment and disability progression in primaryprogressive multiple sclerosis

J. Lorscheider (Melbourne, AU)

Contribution of inflammation to disability accrual in primary progressive multiple sclerosis T. Kalincik (Melbourne, AU)

Safety and clinical improvement in a phase I trial of autologous Epstein–Barr virus-specific Tcell therapy in patients with progressive multiple sclerosis

M.P. Pender (Brisbane, AU)

Effect of MD1003 (High-Dose Biotin) for the Treatment of Progressive MS: 36-Month Follow-Up Data

A. Tourbah (Reims, FR)

Effect of MD1003 (High-Dose Biotin) in Spinal Progressive Multiple Sclerosis (MS-SPI):Subgroup Analyses

A. Tourbah (Reims, FR)

A multicentre, randomized, double-blind, non-inferiority clinical trial to compare the clinicaland radiological efficacy of 625 mg versus 1250 mg of oral methylprednisolone in patientswith relapse of multiple sclerosis: the Oral-CORTEM trial

C. Ramo-Tello (Badalona, ES)

Title: MS FIRST – utilising a longitudinal, prospective, comparative drug safety module foruse in everyday MS clinical practice to evaluate and track incidence and characteristics ofsafety outcomes in MS patients on therapy over the long term

J. Haartsen (Melbourne, AU)

Effect of Early Switch to Fingolimod From Other Oral Therapies in Patients WithRelapsing–Remitting Multiple Sclerosis


The rapid efficacy of natalizumab vs fingolimod in patients with active relapsing-remittingmultiple sclerosis: results from REVEAL, a randomised, head-to-head phase 4 study


Probiotic VSL3 induces changes in the gut microbiome function and promotes an anti-inflammatory peripheral immune response in Multiple Sclerosis patients

S. Tankou (Boston, US)

/ 97


Patient Characteristics, Safety, and Preliminary Results of a Placebo Controlled, Phase 2aMulticenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 MonoclonalAntibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis

E.J. Fox (Round Rock, US)

Variability in adverse event reporting and reasons for discontinuations with dimethylfumarate: Results from a generalized linear mixed model

F. Pellegrini (Zug, CH)

Overcoming therapeutic inertia in multiple sclerosis care: A pilot randomized trialevaluating an educational intervention

G. Saposnik (Toronto, CA)

Siponimod Pharmacokinetics, Safety and Tolerability in Combination with the CYP2C9/3A4Inducer, Rifampin in Healthy Subjects

A. Gardin (Basel, CH)

No Evidence of Disease Activity status among patients with relapsing-remitting multiplesclerosis on long-term natalizumab treatment: data from a real-world cohort in the CzechRepublic

D. Horáková (Prague, CZ)

Preliminary results of Phase 2 Multicenter Study of Ublituximab (UTX), a novelglycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms ofMultiple Sclerosis (RMS) demonstrates rapid Gd-enhancing lesions decrease

M. Inglese (New York, US)

Treatment of Neuromyelitis Optica Spectrum Disorders with Methotrexate: experience of aspecialist center in Brazil

M.S. Pitombeira (Sao Paulo, BR)

Pilot results of a web based patient decision aid for first-line treatment of relapsing-remitting multiple sclerosis patients

E. Lapointe (Vancouver, CA)

U.S. Payers’ Views on Expansion of Patient Access to Disease-Modifying Therapies (DMTs)for Multiple Sclerosis

D. Robertson (Tampa, US)

The effect of Fampridine treatment on cognition: Two year prospective study S. Ozakbas (Izmir, TR)

Efficacy of an internet-based program (MS Intakt) to promote physical activity afterinpatient rehabilitation in persons with multiple sclerosis – a randomized controlled study

P. Flachenecker (Bad Wildbad, DE)

Aspirin improves exercise endurance in multiple sclerosis: Pilot findings from a double-blindrandomized placebo-controlled crossover trial

V.M. Leavitt (New York, US)

Relapse Prevalence, Symptoms, and Healthcare Engagement: Insights from Patients withMultiple Sclerosis from the Multiple Sclerosis in America 2017 Survey

T. Nazareth (Hampton, US)

/ 97


Remotely Supervised Transcranial Direct Current Stimulation (RS-tDCS) Improves Fatigue inMultiple Sclerosis

L.E. Charvet (New York, US)

Walking Economy, as Measured by Decreased Oxygen Demand, is Improved in MultipleSclerosis Patients Responding to Fampridine

K.J. Riess (Edmonton, CA)

A systematic review of everyday memory measures in multiple sclerosis R. das Nair (Nottingham, GB)

MS Relapse Treatments and Relapse Resolution: Retrospective Study Results from a USHealth Plan

T. Nazareth (Hampton, US)

FAMPRIDINE EFFECTS ON UPPER LIMBS MOTOR FUNCTION AND QUALITY OF LIFE A.N. Lagorio (Santiago de Compostela, ES)

Mental processment velocity in patients on treatment with Fampridine M. Puente Hernández (Santiago de Compostela, ES)

Intrathecal baclofen is an effective treatment for ambulatory subjects with MS relatedspasticity

Y. Sammaraiee (London, GB)

Comparative effectiveness of natalizumab and fingolimod treatment on cognitive outcomesin relapsing multiple sclerosis patients

P. Iaffaldano (Bari, IT)

Comparing patient and healthcare professional perceptions on multiple sclerosismanagement and care – where do their priorities differ? Results from a qualitative survey

P. Rieckmann (Bamberg, DE)

Intensive social-cognitive program (Can Do Treatment) in patients with relapsing remittingmultiple sclerosis and low disability: a randomized controlled trial

P.J. Jongen (Groningen, NL)

Octogenarians with MS: A study describing lifestyle factors of the oldest old living withMultiple Sclerosis

M. Ploughman (St. John's, CA)

Laughing Matters: The Role of Humor on Psychological Well-being, Health, & Quality of Lifein Multiple Sclerosis (MS)

L. Strober (West Orange, US)

Combined T25FW and MSWS12 response improves identification of persistent response toPR-Fampridine in people with MS

R.A.L. Ewe (London, GB)

Preliminary findings in persons with Multiple Sclerosis with cognitive impairment showimprovement with computerized three-dimensional Multiple Object Tracking Training

J.R. St.Onge (Regina, CA)

/ 97


High levels of alexithymia may contribute to the complex affective traits found in patientswith multiple sclerosis

Y.D. Fragoso (Santos, BR)

Validation of MUSIQOL among Arabic-speaking MS Patients treated with High dose INF-β 1asc injection New Formulation

M. Al Jumah (Riyadh, SA)

Equivalence of the electronic versus paper-based short version of the MSQOL-54(MSQOL-29)

A. Solari (Milan, IT)

Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY): An independent analysis ofthe quality of life data

D. Afolabi (London, GB)

Coping strategies, health-related quality of life and life satisfaction among persons withmultiple sclerosis

M. Bassi (Milano, IT)

"Patient satisfaction and quality of life during treatment with fingolimod in multiplesclerosis: Results from the ‘DIAMOND’ non-interventional, prospective, observational studyin Greece"

E. Zafeiropoulou (Athens, GR)

RebiQoL: A telemedicine patient support program on health related quality of life andadherence in MS patients treated with Rebif

A.-M. Landtblom (uppsala, SE)

Physical activity impacts positively on depression and objective sleep in patients with MS D. Sadeghi Bahmani (Basel, CH)

Profiles of Patient-Reported Outcomes as Predictors of Treatment Type in MultipleSclerosis: A Discriminant Function Analysis of Disease Modifying Treatment

L.D. Medina (Aurora, US)

Social Media Session, Hall D15:45 - 16:45 Burning debate - Rumble in the Jungle: B cells vs. T cells

This burning debate will address the topical issue of MS being a T-cell mediateddisease and that B-cells are less important. Votes will be cast via twitter using#burningdebate

ChairsD. Wraith (Birmingham, GB)

15:45 - 16:15 Against S. Hauser (San Francisco, US)

16:15 - 16:45 For D.A. Hafler (North Haven, US)

/ 97


Hot Topic Sessions, Hall A17:00 - 17:45 Hot Topic 3: Controversy 1: RIS: should it be treated?

ChairsO. Kantarci (Rochester, US)A. Siva (Istanbul, TR)

17:00 - 17:20 For D.T. Okuda (Dallas, US)

17:20 - 17:40 Against C. Lebrun (Nice, FR)

17:40 - 17:45 Summary O. Kantarci (Rochester, US)

Hot Topic Sessions, Hall B17:00 - 17:45 Hot Topic 4: New insight in neurobiology / how the active

brain stimulates repair?

ChairsA. Baron-Van Evercooren (Paris, FR)D. Fields (Bethesda, US)

17:00 - 17:15 Why oligodendrocytes preferentially myelinate electrically active axons M.C. Angulo (Paris, FR)

17:15 - 17:30 How neuronal activation can impact myelination and function in vivo B. Emery (Portland, US)

17:30 - 17:45 Can brain stimulation influence repair in MS? L. Leocani (Milan, IT)

Hot Topic Sessions, Hall C17:00 - 17:45 Hot Topic 5: Cognition and cognitive remediation in MS

ChairsB. Brochet (Bordeaux, FR)M.P. Amato (Florence, IT)

17:00 - 17:15 Brain connectivity and cognitive impairment in MS C. Louapre (Paris, FR)

17:15 - 17:30 Psychiatric disorders and their relationship (interplay) with cognitiveimpairment in MS

A. Feinstein (Toronto, CA)

17:30 - 17:45 Therapeutic management of cognitive impairment in MS L. Krupp (Stony Brook, US)

/ 97


Hot Topic Sessions, Hall D17:00 - 17:45 Hot Topic 6: Gut microbiota in multiple sclerosis

ChairsH. Weiner (Boston, US)R. Du Pasquier (Lausanne, CH)

17:00 - 17:15 How microbiota shapes mucosal immunity and immunopathology H. Wekerle (Munich, DE)

17:15 - 17:30 Gut microbiome in central nervous system autoimmunity L. Kasper (Hanover, US)

17:30 - 17:45 Dysbiosis in the gut microbiota of patients with MS H. Tremlett (Vancouver, CA)

Satellite Symposia, Hall A18:00 - 19:00 Satellite Symposium

Supported by Merck

Satellite Symposia, Hall B19:15 - 20:15 Satellite Symposium - Navigating choice: mastering the

multiple facets of MS management

Supported by Biogen International

/ 97


Friday, 27 October 2017

Satellite Symposia, Hall A08:00 - 09:00 Satellite Symposium - Potential solutions to treatment

burden in MS

Supported by Merck

Free Communications, Hall A09:15 - 10:15 Free Communications 1

ChairsR. Franklin (Cambridge, GB)B. Segal (Ann Arbor, US)

09:15 - 09:27 Identification of oligodendroglial secreted factors inducing nodal proteinclustering in the central nervous system

A.-L. Dubessy (Paris, FR)

09:27 - 09:39 Reduced microglial activation through the inhibition of colony-stimulating factor 1 receptor (CSF1R) to promote remyelination andneuroprotection

J. Correale (Buenos Aires, AR)

09:39 - 09:51 Side effects of long-term rituximab treatment in NMOSD patients:hypogammaglobulinemia and impairment of specific humoral immunity

A. Bertolotto (Orbassano, IT)

09:51 - 10:03 The potency of the interaction between smoking and HLA MS risk genesdepends on number of HLA risk alleles

L. Alfredsson (Stockholm, SE)

10:03 - 10:15 Autoantibody profile (MOG-IgG-seropositive, AQP4-IgG-seropositive andseronegativity) as a visual outcome predictor after optic neuritis

L.M. Ventura (São Paulo, BR)

Free Communications, Hall B09:15 - 10:15 Free Communications 2

ChairsF. Barkhof (Amsterdam, NL)S. Ludwin (Kingston, CA)

09:15 - 09:27 Detection and characterisation of slowly evolving lesions in multiplesclerosis using conventional brain MRI

C. Elliott (Montreal, CA)

/ 97


09:27 - 09:39 Lesion activity relates to clinical course and gender in the multiplesclerosis autopsy cohort of the Netherlands Brain Bank

I. Huitinga (Amsterdam, NL)

09:39 - 09:51 The varying contribution of normal aging atrophy to MS brain volumemeasurements across adulthood

C. Azevedo (Los Angeles, US)

09:51 - 10:03 Progression of regional grey matter atrophy in multiple sclerosis A. Eshaghi (London, GB)

10:03 - 10:15 Inhomogeneous Magnetization Transfer (ihMT) in normal-appearingtissue correlates with disability of multiple sclerosis patients

S. Mchinda (Marseille, FR)

Free Communications, Hall C09:15 - 10:15 Free Communications 3

ChairsR. Gold (Bochum, DE)T. Kilpatrick (Melbourne, AU)

09:15 - 09:27 Biosensor measures in clinic and free-living settings correlate withmultiple sclerosis disease severity

T. Chitnis (Boston, US)

09:27 - 09:39 Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes inpatients with relapsing multiple sclerosis in the OPERA studies

L. Balcer (New York, US)

09:39 - 09:51 Peripapillary retinal nerve fibre layer as measured by optical coherencetomography is a prognostic biomarker for disability progression inmultiple sclerosis

G. Bsteh (Innsbruck, AT)

09:51 - 10:03 Effects of high frequency repetitive transcranial magnetic stimulation ongait and balance in patients with relapsing remitting multiple sclerosis

H.S. Shehata (Cairo, EG)

10:03 - 10:15 Multiple Sclerosis disease course prediction: a machine learning modelbased on patient reported and clinician assessed outcomes

A. Tacchino (Genova, IT)

Free Communications, Hall D09:15 - 10:15 Free Communications 4

ChairsE. Kubala Havrdová (Prague, CZ)H.-P. Hartung (Düsseldorf, DE)

/ 97


09:15 - 09:27 Patients with paediatric-onset multiple sclerosis are at higher risk ofcognitive impairment in adulthood: an Italian collaborative study

L. Ruano (Porto, PT)

09:27 - 09:39 Long-term Multiple Sclerosis prognosis as a consequence of treatmentpattern changes: a recent update

C. Cordioli (Montichiari, IT)

09:39 - 09:51 Relapses in patients with secondary progressive MS: a matter of diseaseduration or age?

K. Ahrweiller (Rennes, FR)

09:51 - 10:03 Does ‘benign’ multiple sclerosis exist? A 30-year follow-up study ofpeople presenting with clinically isolated syndrome

K.K. Chung (London, GB)

10:03 - 10:15 Course of disease of initially benign multiple sclerosis patients: Long-term follow-up results of physical disability and cognitive impairment

A. Manouchehrinia (Stockholm, SE)

Parallel Sessions, Hall A10:45 - 12:15 Parallel Session 10: Safety issues in MS therapeutic

management

ChairsM.S. Freedman (Ottawa, CA)P.S. Soerensen (Copenhagen, DK)

10:45 - 11:05 Safety issues of MS therapeutics (excluding PML) M. Clanet (Toulouse, FR)

11:05 - 11:25 PML risk of MS therapeutics D.B. Clifford (St Louis, US)

11:25 - 11:40 Preventable side effects of Alemtuzumab N. Scolding (Bristol, GB)

11:40 - 11:52 Long-term exposure to natalizumab during pregnancy – a prospectivecase series from the German Multiple Sclerosis and Pregnancy Registry

T. Kümpfel (Munich, DE)

11:52 - 12:04 Pregnancy Outcomes in Patients With MS Treated With Teriflunomide:Clinical Study and Post-Marketing Data

S. Vukusic (Lyon, FR)

12:04 - 12:16 Long-term Safety of Daclizumab Beta in Patients with Relapsing MS inEXTEND: Interim Results From Treatment up to 6 years

S. Cohan (Portland, US)

/ 97


Parallel Sessions, Hall B10:45 - 12:15 Parallel Session 11: Genes and environment in MS

ChairsJ. Correale (Buenos Aires, AR)P. De Jager (New York, US)

10:45 - 11:05 Gene-environment interactions in MS P. Strid (Stockholm, SE)

11:05 - 11:25 Viral infections as triggers of MS J. Lünemann (Zurich, CH)

11:25 - 11:37 Incidence of multiple sclerosis in Danish women has doubled over thelast sixty with an only modest increase in men

M. Magyari (Copenhagen, DK)

11:37 - 11:49 Whole-Genome sequencing in primary progressive multiple sclerosisuncovers mutations in genes for inherited leukodystrophies and other MSphenocopies

X. Jia (San Francisco, US)

11:49 - 12:01 Epstein-Barr virus, 25-hydroxyvitamin D and risk of multiple sclerosisamong women in the Finnish Maternity Cohort

K. Munger (Boston, US)

12:01 - 12:13 Promoting healthier lifestyle contributes to averting multiple sclerosislong-term societal and healthcare costs: results from the VoT Project

M. Pugliatti (Ferrara, IT)

Parallel Sessions, Hall C10:45 - 12:15 Parallel Session 12: Long term disability evolution:

contributions from cohorts and clinical trials

ChairsS. Dhib Jalbut (New Brunswick, US)L. Kappos (Basel, CH)

10:45 - 11:05 Disability progression in MS: insight from MS cohorts S. Vukusic (Lyon, FR)

11:05 - 11:25 Disability progression in MS: contribution from clinical trials B.A. Cree (San Francisco, US)

11:25 - 11:37 Risk of multiple sclerosis disability milestones decreased over the lastdecade: a nationwide population-based cohort study in Sweden

O. Beiki (Stockholm, SE)

11:37 - 11:49 Impact of oral contraceptives and menopause on MS risk and prognosis:results from the Barcelona CIS cohort

S.O.-R. Graells (Barcelona, ES)

/ 97


11:49 - 12:01 Longitudinal Changes in Quantitative Spinal Cord MRI in MultipleSclerosis Patients: Preliminary Results of a 5-year Study

J. Oh (Toronto, CA)

12:01 - 12:13 Beta-interferon and mortality in multiple sclerosis: A population-basedinternational study

E. Kingwell (Vancouver, CA)

Satellite Symposia, Hall A12:45 - 13:45 Satellite Symposium - The evolution of MS treatment:

moving towards optimized treatments

Supported by Celgene

Satellite Symposia, Hall C12:45 - 13:45 Satellite Symposium

Supported by Teva

ChairsO. Ciccarelli (London, GB)

Parallel Sessions, Hall A14:00 - 15:30 Parallel Session 13: Update on relapsing-remitting MS

management

ChairsG. Comi (Milan, IT)P. Vermersch (Lille, FR)

14:00 - 14:20 AAN guidelines A. Rae-Grant (Cleveland, US)

14:20 - 14:40 ECTRIMS-EAN guidelines X. Montalban (Barcelona, ES)

14:40 - 14:52 Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis


14:52 - 15:04 Ozanimod Demonstrates Efficacy and Safety in a Phase 3 Trial ofRelapsing Multiple Sclerosis (SUNBEAM)

G. Comi (Milan, IT)

15:04 - 15:16 CONCERTO: A Placebo-Controlled Trial of Oral Laquinimod in PatientsWith Relapsing-Remitting Multiple Sclerosis

G. Comi (Milan, IT)

/ 97


15:16 - 15:28 Aerobic exercise induces functional and structural reorganisation of thebrain network: Results from a randomized controlled trial in relapsing-remitting Multiple Sclerosis

J.-P. Stellmann (Hamburg, DE)

Parallel Sessions, Hall B14:00 - 15:30 Parallel Session 14: Remyelination: from biology to clinical

trials

ChairsP. Casaccia (New York, US)B. Zalc (Paris, FR)

14:00 - 14:20 New screening tools and candidates for myelin repair B. Nait Oumesmar (Paris, FR)

14:20 - 14:40 Stem cells (Ips) and remyelination F. Sim (Buffalo, US)

14:40 - 14:52 NFAT as a key regulator of oligodendroglial differentiation K. Groll (Münster, DE)

14:52 - 15:04 Sigma 1 Receptor Agonists as Potential Protective and ReparativeTherapy in Multiple Sclerosis

R.P. Lisak (Detroit, US)

15:04 - 15:16 Single-cell RNA-sequencing profiling of oligodendrocyte lineage cellsisolated from the Multiple Sclerosis mouse model EAE

A.M. Falcao (Stockholm, SE)

15:16 - 15:28 Pathological correlates of magnetization transfer ratio in multiplesclerosis

M. Moccia (London, GB)

Parallel Sessions, Hall C14:00 - 15:30 Parallel Session 15: Metabolic and molecular imaging of

MS

ChairsJ. Pelletier (Marseille, FR)M.A. Rocca (Milan, IT)

14:00 - 14:20 Myelin repair and neurodegeneration in MS: lessons from PET studies B. Bodini (Paris, FR)

14:20 - 14:40 High field MRI imaging in MS M. Inglese (New York, US)

/ 97


14:40 - 14:52 3T MRI DETECTION OF 7T PARAMAGNETIC RIMS IN MULTIPLE SCLEROSISLESIONS: A STEP TOWARD THE CLINICAL APPLICATION

M. Absinta (Bethesda, US)

14:52 - 15:04 A gradient of periventricular microglial activation suggests a CSF-derivedneurodegenerative component in MS

E. Poirion (Paris, FR)

15:04 - 15:16 Two years progression of neurodegeneration in RRMS: metabolicabnormalities topography using 3D MRSI

M. Donadieu (Marseille, FR)

15:16 - 15:28 [18F]GE-180, a novel TSPO-PET tracer for visualization of inflammatoryCNS-activity in MS

C. Mahler (München, DE)

Poster Sessions, Poster Exhibition Poster Session 2

Characteristics of acute transverse myelitis in CLIPPERS G. Taieb (Montpellier, FR)

Neuromyelitis optica spectrum disorders: short myelitis lesions on magnetic resonanceimaging in a cohort of Latin American patients


2015 International Panel for NMO Diagnosis criteria improves early NMOSD diagnosis in aColombian cohort

M. Zuluaga (Medellin, CO)

HoxB3, a novel biomarker that predicts conversion to multiple sclerosis E. Tüzün (Istanbul, TR)

Omics-based approach reveals complement-mediated inflammation in CLIPPERS andpotential biomarkers differentiating from RRMS

Z. Illes (Odense, DK)

The Utility of Brain Lesion Distribution Criteria at Onset in the Distinction of MultipleSclerosis, Neuromyelitis Optica Spectrum Disorder and MOG-IgG Encephalomyelitis

J.-W. Hyun (Goyang, KR)

Rates and predictors of misdiagnosis in primary progressive multiple sclerosis (PPMS) inEurope and the United States

J. White (London, GB)

ARE THE PATTERNS OF VISUAL EVOKED POTENTIAL IN PATIENTS WITH RELAPSINGINFLAMMATORY OPTIC NEURITIS SIMILAR TO THOSE OF MULTIPLE SCLEROSIS OR OPTICALNEUROMYELITIS?

S. Pessanha Neto (Rio de Janeiro, BR)

Clinical characteristics of MOG associated Central Nervous System inflammatory disordersin adulthood

A. Bertolotto (Orbassano, IT)

/ 97


‘Sixteen syndrome’- Three Cases of Multiple Sclerosis Presenting with Pontine Lesions M. Hu (Swansea, GB)

Accuracy of the central vein sign evaluation by brain MRi for the pathologic characterizationof multiple sclerosis cases with markers of “better explanation” of the diagnosis

L. Massacesi (Florence, IT)

Sensitivity and specificity of cerebrospinal fluid free light chains in Argentinean patientswith suspected multiple sclerosis

M.S. Sáez (Buenos Aires, AR)

The Diagnostic Utility of Screening for Multiple Sclerosis Mimics A. Shah (Ann Arbor, US)

Specificity of 3T FLAIR* MRI Demonstration of Central Vessel Sign in Three Lesions forDiagnosis of Multiple Sclerosis

A.J. Solomon (Burlington, US)

The Clinical and Radiological Outcomes of Tumefactive Multiple Sclerosis A. Fontes-Villalba (St Leonards, AU)

A Retrospective Comparison of Rituximab Vs Cyclophosphamide In Neuromyelitis OpticaSpectrum Disorders Patients

M. Radaelli (Milan, IT)

"Unicuique suum": cerebellar lobule atrophy and disability in multiple sclerosis phenotypes M. Petracca (New York, US)

Neuromyelitis optica spectrum disorder and rituximab: a multi-center analysis G. Novi (Genoa, IT)

Motor Progression from a Single Critically Located Demyelinating Lesion in PauciscleroticMS

M. Keegan (Rochester, US)

Survival in patients with neuromyelitis optica spectrum disorders: data from the Belgradecohort

I.P. Dujmovic Basuroski (Belgrade, RS)

MOG-antibody-positive CNS demyelinating disease: A clinical study in Chinese Han patients J. Zhangbao (Shanghai, CN)

Month or season of birth effect on developing neuromyelitis optica spectrum disorder inKorea

W. Kim (Seoul, KR)

The diagnosis of OCB-negative MS-patients - an inventory of the Swedish MS register inUppsala, Sweden

A.-M. Landtblom (uppsala, SE)

Autoimmune encephalitis in patients with anti-myelin oligodendrocyte glycoprotein-antibody

R. Ogawa (Sendaishi, JP)

/ 97


Cortical grey matter thickness is more impaired in primary progressive multiple sclerosis ascompared to relapsing-remitting disease course

K. Pardo (Tel Aviv, IL)

BRAIN VOLUME LOSS IN RADIOLOGICALLY ISOLATED SYNDROMES COMPARED WITH EARLYSTAGES OF MULTIPLE SCLEROSIS PATIENTS UNDER DMD TREATMENT

J.I. Rojas (Buenos Aires, AR)

Environmental toxic exposures are associated with risk for pediatric-onset multiplesclerosis

S. Mar (St. Louis, US)

Treatment of highly active multiple sclerosis in pediatric patients P. Huppke (Göttingen, DE)

Relationship of sex and physical activity level to depression and fatigue in pediatricdemyelinating disease: a longitudinal study

S. Stephens (Toronto, CA)

Altered Adipocytokine Levels in Pediatric Multiple Sclerosis K. Keyhanian (Boston, US)

Anti-JC virus antibodies in pediatric multiple sclerosis patients K. Sadowski (Warsaw, PL)

Diagnostic criteria in the evaluation of children with a first demyelinating episode:prospective Spanish national cohort

G. Arrambide (Barcelona, ES)

Neuroimaging profile in pediatric Neuromyelitis Optica Spectrum Disorders (NMOSD) R. Paolilo (São Paulo, BR)

Multiple Sclerosis: the impact in the newborn J. Ribeiro (Coimbra, PT)

Systematic literature review on the effectiveness and safety of treatments in paediatricmultiple sclerosis

M.C. Vieira (East Hanover, US)

Spectrum of Late onset Neuromyelitis Optica (L-NMOSD): Experience from NIMHANSBengaluru, South India

H. Bollampalli (Bangalore, IN)

Benign multiple sclerosis: does the initial outcome predict a favorable long term evolution? E. Matas (L'Hospitalet de Llobregat, ES)

Association between quality of life and self-reported disability in MS PATHS patients D. Miller (Cleveland, US)

Disease activity persists in long-term progressive MS B. Rodríguez-Acevedo (Barcelona, ES)

Disability progression variability in different ages at diagnosis of multiple sclerosis B. Wong (Providence, US)

/ 97


Diffusion tensor imaging in multiple sclerosis at different final outcomes O. Andersen (Göteborg, SE)

SUMMIT: Initial insights from a repository of deeply phenotyped multiple sclerosis cohorts R. Bove (San Francisco, US)

Baseline and time-dependent predictors of clinical disability progression in a pooled sampleof phase 3 clinical trial placebo arms

B.C. Kieseier (Zug, CH)

The influence of menopause in Multiple Sclerosis course F.F. Ladeira (Lisbon, PT)

Disability severity in a real world MS population: Results from the MS PATHS LearningHealth System


Prescription medication exposure and the risk of multiple sclerosis: a systematic review H.Y. Yong (Vancouver, CA)

Age at diagnosis over the last decades – Analysis of the German MS Registry J. Haas (Berlin, DE)

The prevalence and incidence of MS and familial MS in Tehran province, Iran S. Eskandarieh (Tehran, IR)

Using algorithms to identify High Disease Activity Relapsing-Remitting Multiple Sclerosispatients using electronic health record data with natural language processing

A.W. Kamauu (Salt Lake City, US)

Developing United States Integrated Delivery Network (IDN) Claims-Based Algorithms toIdentify Relapses in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients


A population-based prospective study of optic neuritis K.K. Soelberg (Vejle, DK)

Five decades of epidemiological survey definitely discloses a real increase in the incidenceof Multiple Sclerosis in the Veneto Region (North-East) of Italy

F. Grassivaro (Padua, IT)

The body mass index in neuromyelitis optica with aquaporin4-immunoglubulinG: associationwith disease onset and outcomes

S.-H. Baek (Seoul, KR)

Prodromal symptoms of multiple sclerosis in primary care: a case-control study using theUK Clinical Practice Research Datalink (CPRD)

G. Disanto (Lugano, CH)

Cross-sectional study in German MS patients reveals unmet needs with regard topsychiatric comorbidity

H. Faber (München, DE)

/ 97


Lethality rates in Multiple Sclerosis and Neuromyelitis Optic Spectrum Disorders patients ina Brazilian cohort of mixed ancestrality

J.G.D. Farinhas (Rio de Janeiro, BR)

Using United States Integrated Delivery Network (IDN) Electronic Health Records(EHR)/Natural Language Processing (NLP)-Based Algorithms to Identify Relapses inRelapsing-Remitting Multiple Sclerosis (RRMS) Patients


Frequency of Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients inTurkey and Affecting Factors

S. Ozakbas (Izmir, TR)

Cancer risk assessment in Multiple Sclerosis patients in the Eastern Sicily F. Patti (Catania, IT)

Multiple Sclerosis Research Dissemination in the Web: News, Blogs, or Tweets? M.A.A. Sahraian (Tehran, IR)

The impact of menopause on multiple sclerosis: a multicentre retrospective observationalstudy

D. Baroncini (Gallarate, IT)

Rates of Pregnancy in Women With and Without Multiple Sclerosis Over Time M.K. Houtchens (Brookline, US)

Infertility Treatment and Live Birth Rates in Women With and Without Multiple Sclerosis M.K. Houtchens (Brookline, US)

Methylprednisolone concentrations in breast milk and serum in patients with multiplesclerosis treated with IV pulse methylprednisolone

C. Boz (Trabzon, TR)

Impact of body size on MS risk and prognosis: results from the Barcelona CIS cohort S. Otero-Romero (Barcelona, ES)

Clinical outcomes in male and female patients with multiple sclerosis in the treatment era A. Bouley (Providence, US)

Impact of brain atrophy on cognitive motor interference in multiple sclerosis: a dual taskstudy

G. Coghe (Cagliari, IT)

Cognitive Rehabilitation for Attention and Memory in people with Multiple Sclerosis: TheCRAMMS Trial

R. das Nair (Nottingham, GB)

Tonic Spasms in Multiple Sclerosis: A Case Series J.M. Gutman (New York, US)

Abnormal functional connectivity of thalamic sub-regions contributes to fatigue in multiplesclerosis

M. Hidalgo de la Cruz (Milan, IT)

/ 97


A randomized controlled pilot trial of a group spasticity management program versus usualcare in people with multiple sclerosis

C. Hugos (Portland, US)

Association between exercise capacity and cognitive functions in persons with multiplesclerosis

T. Kahraman (Izmir, TR)

A double blind, randomized, placebo controlled, crossover study of the effectiveness of oralfampridine in improving upper limb function in progressive multiple sclerosis

N. McNicholas (Dublin, IE)

Subclinical speech signs correlate with MS disease severity and differentiates patients withand without clinical cerebellar dysfunction

G. Noffs (Melbourne, AU)

Brain reserve and cognitive reserve in progressive multiple sclerosis: resilience againstcognitive effects of neurodegeneration

A. Pepe (New York, US)

Olfactory dysfunction in patients with primary progressive multiple sclerosis F.A. Schmidt (Berlin, DE)

Dual task cost of walking: an unreliable measurement among people with MS and controls M. Ploughman (St. John's, CA)

Evaluation of dysautonomic symptoms in MS patients: use of the Composite AutonomicSymptom Score (COMPASS)-31 questionnaire

L. Mancinelli (Chieti, IT)

Expert consensus on standards for multiple sclerosis care: results from a modified Delphiprocess

J. Hobart (Plymouth, GB)

Creation of a normative data set on subjective and objective measures for upper limbfunction in a large MS population

C. Solaro (Genova, IT)

Cognitive impairment in MS, performance in daily activity and perception: apatient/caregiver study

G. Fenu (Cagliari, IT)

An engineered glove allows a quantitative integrated assessment of motor and cognitiveimpairment in Multiple Sclerosis

E. Gallo (Genova, IT)

The use of distractors within a computerized version of the SDMT reduces practice effects E. Donaldson (Toronto, CA)

Investigation of Cladribine Treatment Rules in Subjects with Relapsing-Remitting MultipleSclerosis (RRMS) by means of Modelling & Simulation

N. Terranova (Lausanne, CH)

/ 97


Long-term predictors of disability worsening in patients with multiple sclerosis in the phase3 FREEDOMS and FREEDOMS II studies

P. Repovic (Seattle, US)

A Kinect-based perceptive assessment battery for motor dysfunction in multiple sclerosisand other neuroinflammatory disorders

K. Otte (Berlin, DE)

Title: Retinal measures correlate with cognitive impairment in patients with MS comparedto healthy controls

K.S. Pandey (Livingston, US)

MRI brain atrophy measures and processing speed in a cohort of MS patients R. Fakih (Beirut, LB)

Improved Clinical Detection of Cerebellar Lesions in Early MS Patients O. Ayeni (New York, US)

Is the EDSS a proxy for non-motor disability across multiple sclerosis disease types? R.J. Mills (Preston, GB)

Validation of stroop color word test as a cognitive task for evaluating cognitive motorinterference during walking in Multiple sclerosis

G. Coghe (Cagliari, IT)

Validity and reliability of smartphone-accelerometry for the measurement of posturalcontrol in people with multiple sclerosis

D. Barbado (Elche, ES)

Validity of self-assessment of functional performance in by MS patients as part of routinepatient care

R.A. Bermel (Cleveland, US)

Clinic to In-Home Telemedicine reduces barriers to care for MS/Neuroimmunology patients R. Bove (San Francisco, US)

Model (PHREND) for personalized prediction of treatment response in relapsing remittingmultiple sclerosis (RRMS)

S. Braune (Prien, DE)

The Effectiveness of Computerized Screening in Detecting Cognitive Deficits in People withMultiple Sclerosis


Cognitive function predicts work disability among multiple sclerosis patients A. Kavaliunas (Stockholm, SE)

The impact of fingolimod on the economic burden of multiple sclerosis: Results from twonon-interventional studies conducted in Germany


Out of Pocket Costs for Healthcare in the US: a NARCOMS, NMSS, iConquerMS Survey S.S. Cofield (Birmingham, US)

/ 97


Disease modifying therapy and health care resource utilization in multiple sclerosis J.J. Marriott (Winnipeg, CA)

Cost utility of oral high-dose corticosteroid treatment for multiple sclerosis relapses D. Veillard (Rennes, FR)

Subclinical retinal pathology resembling multiple sclerosis in myelin-oligodendrocyte-glycoprotein antibody-positive patients during follow-up

J. Havla (Munich, DE)

In Vivo Detection of Retinal Arteriolar Occlusions in Neuromyelitis Optica: A Case-ControlStudy with MultiColor Optical Coherence Tomography

J.M. Lam (Philadelphia, US)

Optimal Inter-Eye Difference Thresholds in Retinal Nerve Fiber Layer Thickness forPredicting a Unilateral Optic Nerve Lesion in MS

L. Balcer (New York, US)

Study of subclinical oculomotor disturbances by video-oculography in individuals withradiological isolated syndrome

M. De verdal (Nimes, FR)

Are saccadic eye movements related to cognitive function in multiple sclerosis? J.A. Nij Bijvank (Amsterdam, NL)

Comorbidity in multiple sclerosis in northeastern Poland K. Kapica-Topczewska (Bialystok, PL)

Multiple Sclerosis in Chile: demographics, clinical phenotypes and comorbidities E. Ciampi (Barcelona, ES)

Comorbid Autoimmunity Is Not a Prognostic Factor in Multiple Sclerosis T. Gündüz (Istanbul, TR)

Cancer risk in multiple sclerosis N. Grytten (Bergen, NO)

Impact of Insulin Resistance And Metabolic Syndrome On Disability And Disease ProgressionIn Patients With Multiple Sclerosis

A. Hassan (Cairo, EG)

Symptoms of depression and use of anti-depressants in MS PATHS (Multiple SclerosisPartners Advancing Technology and Health Solutions) patients

D. Miller (Cleveland, US)

Prevalence of Comorbidities in Patients With and Without Multiple Sclerosis by Age andSex: A US Retrospective Claims Database Analysis

A.L. Phillips (Rockland, US)

Corpus Callosum Index in MS patients with and without Epilepsy R. Uribe-San-Martin (Santiago, CL)

A Phenome-wide Examination of the Comorbidity Burden Associated with Multiple SclerosisDisease Severity

Z. Xia (Boston, US)

/ 97


Glial iron dysregulation in multiple sclerosis brains S. Hametner (Vienna, AT)

Molecular signature of Epstein-Barr virus infection in multiple sclerosis brain lesions M.H. Han (Stanford, US)

Systemic vascular disease burden and multiple sclerosis pathology: a post mortem study R. Geraldes (Oxford, GB)

Disease activity and site related expression of microRNAs in astrocytes in multiple sclerosis V.T. Rao (Montreal, CA)

The meningeal compartment supports tertiary lymphoid organogenesis in a natural modelof multiple sclerosis

J. Alvarez (Philadelphia, US)

Metabolomic screening of cerebrospinal fluid from multiple sclerosis patients reveals adistinct signature

F. Mir (New York, US)

Dynamics of tissue regulatory T cells in Neuromyelitis optica spectrum disorders lesions F. Yanagimura (Niigata, JP)

Association between CD20+ B-cells and age at death in multiple sclerosis M. Moccia (London, GB)

Fingolimod activates the 5-HT1A receptor in S1P3R/5-HT1A heterooligomer complexes invivo

K. Dines (San Diego, US)

Experimental autoimmune encephalomyelitis (EAE) on a background of chronic microgliaactivation, iron accumulation and neurodegeneration: Unexpected neuropathologicalfindings in the Zitter rat model

I. Wimmer (Vienna, AT)

Altered quality and quantity of Axon Initial Segment and Nodes of Ranvier in different MSmouse models

C. Ertl (Munich, DE)

Evaluation of the impact of reducing A20 expression in myeloid cells: study in a murinemodel

F. Montarolo (Orbassano, IT)

The effect of glatiramer acetate (GA) on cognitive function in an animal model of multiplesclerosis

R. Aharoni (Rehovot, IL)

Sensitization of superior dominant peptide may eradicate relapsing and progressivemultiple sclerosis by sequential induction of stabilized antigen-specific hybrid regulatory Tcells reactive to disease-associated antigens with tissue-repair capacity

Y. Lin (Tokyo, JP)

Evaluation of vitamin D on the activation of neurogenesis and adult gliogenesis in a modelof acute demyelination

V. Pytel (Madrid, ES)

/ 97


Establishing an in vitro human cell culture based model for inflammation-related neuronaldamage and regeneration in multiple sclerosis

S. Rasehorn (Berlin, DE)

Meningeal inflammation correlates with neurodegeneration and glial activation in a chroniccortical focal animal model of Multiple Sclerosis

B.A. Silva (Buenos Aires, AR)

The NKG2D ligand RAE-1 is induced in the CNS during experimental autoimmuneencephalomyelitis and its expression correlates with microglia cell proliferation

J. Boucraut (Marseille, FR)

Expanding the behavioural characterization of the cuprizone mouse model: what changeswill be most sensitive to early remyelination?

F. Palavra (Coimbra, PT)

CD44 as a trigger for inflammatory lesion formation T. Hochstrasser (Munich, DE)

Effect of MS associated IL2RA gene variants on CD4+ T cell subsets in genotype-selectedhealthy controls

S. Buhelt (Copenhagen, DK)

Epigenetic profiling of bronchoalveolar lavage cells in multiple sclerosis and associations tocigarette smoking

M.V. Ringh (Stockholm, SE)

HLA-DRB1 polymorphism and susceptibility to multiple sclerosis in the Middle East NorthAfrica region: Systematic review and meta-analysis reveals similarities with Caucasians

B. Mohajer (Tehran, IR)

miR-29b: microRNA biogenesis and dysregulation meets DNA hypermethylation in SPMS K.A. Sanders (Hull, GB)

Multiple Sclerosis and HLA genotypes: a possible influence on brain atrophy L. Lorefice (Cagliari, IT)

The distribution of courses of multiple sclerosis (MS) in familial MS. A population basedDanish register study

M. Steenhof (Odense, DK)

Genetic variation in the gene LRP2 increases relapse risk in multiple sclerosis Y. Zhou (Hobart, AU)

MicroRNA-155 circulating levels in Portuguese Multiple Sclerosis patients A. Bettencourt (Porto, PT)

Plasma platelet microparticle counts are elevated in multiple sclerosis and regulated by thefunction of the platelet P2X7 receptor

J. Wong (Melbourne, AU)

Differential intrathecal inflammatory markers in acute optic neuritis and later conversion tomultiple sclerosis

M.N. Olesen (Vejle, DK)

/ 97


Investigation of the function and phenotype of CD20+ T cells in MS and control patients E. Rathbone (Birmingham, GB)

Dysregulation of Granulocyte-Macrophage Colony-Stimulating Factor in Multiple SclerosisOccurs across Immune Cell Lineages

J. Aram (Nottingham, GB)

Discovering a new pathogenic CD20+ T cell population implicated in multiple sclerosis M.R. von Essen (Copenhagen, DK)

GPR15+ CD4+ T cells are more reactive in smokers and enriched in CSF from patients withRRMS

C. Ammitzbøll (Copenhagen, DK)

T follicular helper/regulatory lymphocyte ratio (TFH/TFR) correlates with the intrathecal IgGsynthesis in multiple sclerosis patients at clinical onset

M. Puthenparampil (Padua, IT)

Leukocyte repopulation following alemtuzumab treatment in relapsing-remitting MScontains multiple regulatory immune cell types

W. Gilmore (Los Angeles, US)

Characterization of ILC subsets in CNS and small intestine during EAE D. Brunotte-Strecker (Berlin, DE)

CD161 intermediate expression defines a novel activated, inflammatory and pathogenicsubset of CD8+ T cells involved in multiple sclerosis

D. Laplaud (Nantes Cédex, FR)

Detection of Myelin-reactive CD8+ T cells in Multiple Sclerosis J.J. Sabatino, Jr (San Francisco, US)

Enhanced expression of IL-22 and GM-CSF by IL-17-producing cerebrospinal fluid T cells inRRMS

L. Ghezzi (Milano, IT)

Mitochondrial dysfunction in peripheral blood mononuclear cells from multiple sclerosispatients

L. Nogueras Penabad (Lleida, ES)

The role of neutrophil-to-lymphocyte ratio in multiple sclerosis and optic neuritis A.K. Bisgaard (Glostrup, DK)

Compartmental constraints on B cell antigen presentation in an MHCII-dependent model ofautoimmune neuroinflammation

C.R. Parker Harp (St. Louis, US)

Cross-reactivity of antibodies with Neural Precursor Cells in Experimental AutoimmuneEncephalomyelitis

N. Grigoriadis (Thessaloniki, GR)

Early, norepinephrine-dependent, activation of the hematopoietic niche and thymusprecedes the onset of EAE

A. Uccelli (Genova, IT)

/ 97


PRN2246, a potent and selective blood brain barrier penetrating BTK inhibitor, exhibitsefficacy in central nervous system immunity

M.R. Francesco (South San Francisco, US)

Cytometry by Time of Flight (CyTOF) shows an increase of T follicular helper-like cells in theCSF of MS patients

N.S. Sanderson (Basel, CH)

Cerebrospinal Fluid Microvesicles: are they useful in Multiple Sclerosis? T. Croese (Milano, IT)

Comprehensive Analysis of the Intrathecal B-cell Response in Patients with MS S.A. Sadiq (New York, US)

Increased concentrations of exosomes in MS patients; are they involved in thepathophysiology of MS?

M. Axelsson (Gothenburg, SE)

Th17 cell mediated neuronal excitotoxicity K. Birkner (Mainz, DE)

Deep sequencing of TCR β-chain repertoire reveals an immune profile signature in MSpatients

A. De Paula A. Sousa (Bethesda, US)

The Anti-Myelin Antibody Response in MS is Primarily Directed Against MyelinOligodendrocyte Glycoprotein

J. Lin (New York, US)

Th17.1 cells as selective contributors to MS disease activity: new perspectives for earlyintervention

M.M. van Luijn (Rotterdam, NL)

Association of human endogenous retroviruses type W with multiple sclerosis S. Macías-Redondo (Zaragoza, ES)

Human Herpesvirus 6 and Cytomegalovirus IgG and IgM antibodies in multiple sclerosispatients: an inverse correlation with age

R. Alvarez-Lafuente (Madrid, ES)

Can antiretroviral drugs suppress endogenous retrovirus expression and protect from MS? E. Morandi (Nottingham, GB)

Wellness factors are related to cerebral grey matter and clinical outcomes in MultipleSclerosis

I. Katz Sand (New York, US)

Case Report: Fecal Microbiota Transplantation Associated with 10 Years of Disease Stabilityin a Patient with Secondary Progressive Multiple Sclerosis

S. Makkawi (Calgary, CA)

Dietary habits, nutritional status and risk of a diagnosis of a first demyelinating event: asingle center incident case-control study

P. Cavalla (Torino, IT)

/ 97


The gut microbiome in active and stable relapsing multiple sclerosis E. Eleftheriou (Worcester, US)

Environmental and genetic factors in MS susceptibility in Spain M.J. Pinto-Medel (Málaga, ES)

Smoking Modulates the Immune Response in Experimental Autoimmune Encephalomyelitisby Activating the Aryl Hydrocarbon Receptor

J. Berg (Bochum, DE)

Vitamin D serum levels and viral load of human herpesvirus 6 and Epstein-Barr virus inpatients with multiple sclerosis after one year of follow-up


Epstein-Barr virus immune response and candidate genetic loci in multiple sclerosispatients and their family members

J.Y. Mescheriakova (Rotterdam, NL)

Beneficial effect of short-chain fatty acids administration in the clinical course ofexperimental autoimmune encephalomyelitis

L. Calvo-Barreiro (Barcelona, ES)

ebv-miR-BART22 is up-regulated in tobacco smoking MS patients M. Muñoz-San Martín (Girona, ES)

Oligodendroglial potassium channel Kir4.1 is essential for white matter function L. Schirmer (San Francisco, US)

Microscopic cellular correlates of macroscopic MRI-measured structural network propertiesin Multiple Sclerosis

S. Kiljan (Amsterdam, NL)

Oligodendrocyte-encoded glutamine synthetase is required for neuro-axonal function L. Ben Haim (San Francisco, US)

Localization of the neuroprotective factor ARNT2 to astrocytes and characterization of itsregulation in experimental models of MS and by inflammatory mediators in vitro

J. Quandt (Vancouver, CA)

The cuprizone model as a valuable tool to study progressive multiple sclerosis K. Fabisch (Munich, DE)

Longitudinal association between deep gray matter atrophy and lesion-based disruptions inconnected white matter tracts


Aging is accelerating central atrophy in MS patients E. Ghione (Buffalo, US)

Novel molecular mechanisms of antibody induced neurodegeneration and spasticity in CNSautoimmune inflammatory disease

H.E. Salapa (Saskatoon, CA)

Corpus callosum atrophy develops within 3 months since CIS trial enrolment L. Tang (Vancouver, CA)

/ 97


Accelerated loss of chronically demyelinated axons in relapsing-remitting multiple sclerosis C. Wang (Sydney, AU)

Beneficial effects of testosterone administration following the onset of clinical symptoms inexperimental model of multiple sclerosis

B. Bielecki (Lodz, PL)

Direct and Indirect Neuroprotective Effects of the Short-Chain Fatty Acid Propionate onHuman Primary Neurons in the Context of Multiple Sclerosis

B. Gisevius (Bochum, DE)

Continuous reorganisation of cortical information flow in MS patients: A longitudinaleffective connectivity study

V. Fleischer (Mainz, DE)

Quantitative comparison of brain volumes as assessed by SPM, SIENA/X and MorphoBoxsoftware packages


Evolution of New Lesions and its Temporal Patterns in Patients with Clinically IsolatedSyndrome Treated with Subcutaneous Interferon Beta-1a

H. Vrenken (Amsterdam, NL)

Metabolites in the posterior cingulate cortex are correlated to clinical symptoms inrelapsing remitting multiple sclerosis

K.A. Ribbons (New Lambton, AU)

Grouping multiple sclerosis patients based on cross-sectional volumetry of whole brain andthalamus

A. Raji (Hamburg, DE)

A deep learning approach for multiple sclerosis lesion segmentation X. Llado (Girona, ES)

INSPIRATION: An approach to brain volume and quantitative lesion load assessments fromstandardized MRI acquisition in daily clinical routine of MS patients


Impact of spinal cord atrophy on daily activity in multiple sclerosis N. Sola-Valls (Barcelona, ES)

Automated Lobe-Specific Classification of Lesions: Correlation with Grey Matter Atrophy B.E. Dewey (Baltimore, US)

Iron loss of Thalamic Nuclei evaluated with quantitative susceptibility mapping is related tointrathecal macrophages activity and cortical pathology of multiple sclerosis

M. Castellaro (Padova, IT)

Brain volume loss in individuals over time: sources of variance and limits of detectability K. Nakamura (Cleveland, US)

The clinical relevance of the network-derived metrics in multiple sclerosis T. Charalambous (London, GB)

/ 97


CSF markers of blood-brain barrier integrity forecast disease progression in early MS J. Kroth (Mainz, DE)

Ultrasmall superparamagnetic iron oxide nanoparticle-enhanced MRI at 7-tesla in multiplesclerosis

M.K. Schindler (Bethesda, US)

[18F]GE180 PET as a sensitive imaging tool to monitor diffuse brain injury A. Nack (Munich, DE)

Thalamic white matter in MS: an MRI study combining DTI and quantitative susceptibilitymapping


Corpus callosum alterations revealed by Diffusion Basis Spectrum Imaging (DBSI) in allstages of multiple sclerosis

A.H. Cross (St. Louis, US)

Depression in multiple sclerosis: Structural and functional disconnection in the fronto-limbicsystem

Q. van Geest (Amsterdam, NL)

Whole white matter integrity predicts information processing speed in clinically isolatedsyndrome and early MS

R.M. Giess (Berlin, DE)

Morphologic MRI phenotyping of multiple sclerosis associates with altered brain function D. Pinter (Graz, AT)

On the Construction of a 3D-Printed Brain Phantom as Gold Standard for the Validation ofBrain Segmentations

A. Altermatt (Basel, CH)

Cognitive impairment in MS: Between cognitive reserve and cerebral atrophy: Aneuropsychological and MRI study

G. Fenu (Cagliari, IT)

Disrupted cerebellar network dynamics and cognitive impairment in progressive multiplesclerosis

M.M. Schoonheim (Amsterdam, NL)

Diffuse reduced axonal density in normal appearing white matter in early multiple sclerosis:novel insights from multi-shell diffusion MRI

C. Mainero (Boston, US)

Deep Learning to Normalize Conventional T1w MRI for Quantitative LongitudinalAssessment of Tissue Health in MS

R.A. Brown (Montreal, CA)

Brain Structural Connectivity in different Clinical Forms of Multiple Sclerosis F. Durand-Dubief (Bron Lyon Cedex, FR)

Diffuse frontal, parietal, temporal and occipital networks play a role in the pathophysiologyof fatigue in multiple sclerosis

M. Palotai (Boston, US)

/ 97


Neuronal dysfunction is less frequent in benign multiple sclerosis: a sodium MRI study A. Maarouf (Marseille, FR)

Is glucose metabolism a proxy for neuroinflammation in MS? A comparative study between18F-FDG and 18F-DPA714 PET

M. Tonietto (Paris, FR)

Relationship between clinical manifestation of MS relapse and Gadolinium enhancinglesions in brain MRI

L. Martín-Aguilar (Badalona, ES)

Dorsal Attention Network and Cognition in MS: a Graph Theoretical Approach at 7-Tesla A.W. Russo (Charlestown, US)

Comparative multi-modal MRI study to examine the effect of Natalizumab, Galtitameracetate and Fingolimod on brain tissue injury in patients with relapsing remitting multiplesclerosis

S. Razmjou (Detroit, US)

Impact of cotinine and vitamin D levels on brain atrophy J. Sastre-Garriga (Barcelona, ES)

The relationship between oxidative stress and symptoms of fatigue and depression inmultiple sclerosis: A pilot study

I.-Y. Choi (Kansas City, US)

Measuring Spinal Cord Atrophy in Chronic Progressive Inflammatory Neurologic Diseases S. Azodi (Bethesda, US)

Conversion to clinically definite multiple sclerosis is associated with lobule-specific atrophyof the cerebellum


Identification of Structural Imaging Correlates of Disability in Neuromyelitis Optica: A GraphTheory Based Approach

C. Chien (Berlin, DE)

Estimating brain atrophy from incompletely acquired clinical MR scans in MS M. Clarke (Nottingham, GB)

Alterations in individual cortical networks of CIS patients: a longitudinal multi-centreMAGNIMS study

S. Collorone (London, GB)

Longitudinal study of MS lesion evolution using neurite orientation dispersion and densityimaging, relaxometry and magnetization transfer imaging

E. Fischi-Gomez (Boston, US)

Results from the Brazilian Brain Volume Studies (B-BRAVOS) database confirm theassociation of volumetric and clinical parameters in multiple sclerosis

Y.D. Fragoso (Santos, BR)

Location of New White Matter Lesions in Multiple Sclerosis: Insights from a Large Dataset L. Gaetano (Basel, CH)

/ 97


Multiple Sclerosis: Brain Atrophy and Computerized Cognitive Testing – A Cross-SectionalPilot Investigation


Reduced iron levels in the DGM of MS patients compared to healthy controls E. Hernández-Torres (Vancouver, CA)

Combined MRI study of perfusion, cerebrovascular reactivity and neurodegeneration inMultiple Sclerosis

M.M. Laganà (Milan, IT)

Ex-vivo MR Microscopy of Cortical Lesions Reveal Iron Loss in Individual Oligodendrocytes G. Nair (Bethesda, US)

Brain Network Organisation and Cognitive Performance in Clinically Isolated Syndromes J. Ooi (London, GB)

Combined analysis of T1- and T2-weighted images to assess microstructural damage.Preliminary results in patients with a clinically isolated syndrome


Impaired structural brain connectome in patients with systemic lupus erythematosus andmultiple sclerosis: a graph theory study

P. Preziosa (Milan, IT)

Impact of vitamin D and cotinine levels on brain atrophy J. Sastre-Garriga (Barcelona, ES)

Relevance of functional connectivity abnormalities to cognitive impairment in neuromyelitisoptica spectrum disoders

F. Savoldi (Milano, IT)

Multi-view convolutional neural networks using batch normalization outperform humanraters during automatic white matter lesion segmentation

M.D. Steenwijk (Amsterdam, NL)

MS cortical lesions classification in different brain areas: comparison between 3D-DIR andmagnetisation-prepared 3D-FLAIR at 3T

F. Tona (London, GB)

Age-dependent whole brain and grey matter annual atrophy rates in healthy adults W. Van Hecke (Leuven, BE)

Declines of N-acetylaspartate (NAA) within 6 month measured by a new MRI-Spectroscopyapproach in the brains of patients with early MS predicts subsequent disability progression

M. Wahl (Frankfurt am Main, DE)

Evidence for neural-vascular uncoupling in multiple sclerosis: a calibrated fMRI study inmotor cortex

K.L. West (Dallas, US)

Retinal damage begins in the ganglion cell layer and correlates with brain atrophy from thevery early stages of the disease in MS patients

T. Carandini (Milan, IT)

/ 97


Visual evoked potentials in acute optic neuritis predict the severity of subsequentneurodegeneration at optical coherence tomography

S.-C. Huang (Milan, IT)

Optical coherence tomography measures correlate with spinal cord area and with disabilityin relapsing multiple sclerosis patients

À. Vidal-Jordana (Barcelona, ES)

Durable neuroprotective effects of alemtuzumab over 5 years on retinal nerve fibre layerand ganglion cell layers in relapsing-remitting multiple sclerosis (RRMS) patients

J.K. Chan (Vancouver, CA)

A Preliminary Investigation into the Relationship between Visual Evoked Potential Latency(VEP-L) and Outcome Parameters from Optical Coherence Tomography (OCT) in People withMultiple Sclerosis


Updates in OCT segmentation software influence longitudinal assessment of retinal atrophy D. Coric (Amsterdam, NL)

Visual pathway involvement in progressive multiple sclerosis: demyelination andneurodegeneration are higher in secondary progressive than primary progressive patients

S. Guerrieri (Milan, IT)

Optical Coherence Tomography and Magnetic Resonance Imaging Correlates with CognitiveImpairment in Patients with Relapsing Remitting Multiple Sclerosis

S. Razmjou (Detroit, US)

Frequent retinal ganglion cell damage after acute optic neuritis A.U. Brandt (Berlin, DE)

The Relationship Between Optical Coherence Tomography and Early NeurocognitiveChanges in Pediatric Multiple Sclerosis

N.M. Shukla (Houston, US)

Revising the Advised Protocol for Optical coherence tomography Study Terminology andElements (APOSTEL): From recommendations to formal guidelines

P. Albrecht (Düsseldorf, DE)

Defining the Anatomical &Physiological Hierarchy of Neuro-Degeneration of the AfferentVisual System in Multiple Sclerosis: A Cross-sectional Study with Spectral Domain OCT,Visual Fields MultiFocal ERG, EDSS, Regional & Whole Brain Atrophy

R. Sergott (Philadelphia, US)

Upper limb motor evoked potentials as outcome of corticospinal involvement in progressiveMS

M. Pisa (Milan, IT)

Measuring cognitive fatigue: PASAT 3” as a quantitative measure in healthy controls andmultiple sclerosis patients

F. García-Vaz (Madrid, ES)

Calibrated fMRI study reveals neural-vascular uncoupling in the visual cortex of multiplesclerosis patients

D.K. Sivakolundu (Richardson, US)

/ 97


Hyperstable EEG-vigilance is associated with activated hypothalamo-pituitary-adrenal (HPA)axis in multiple sclerosis patients

M.G. Stoppe (Leipzig, DE)

How feasible is the application and scoring of BICAMS in daily clinical routine? M. Filser (Düsseldorf, DE)

Detection of cognitive decline in MS using BICAMS: Is there substantial value in applyingthe full battery?

S. Baetge (Düsseldorf, DE)

Education level and the characteristics cognitive impairment in a Brazilian cohort ofmultiple sclerosis patients

C.M. Rimkus (Amsterdam, NL)

Word Finding Deficits in Early Multiple Sclerosis: A Behavioral and NeuroimagingInvestigation

R. Brandstadter (New York, US)

Towards a better understanding of the perception of cognitive symptoms in patients withMultiple Sclerosis

S. Vanotti (Buenos Aires, AR)

Cognitive impairment in MS: are white matter lesions the main driver? C. Engl (Munich, DE)

Impact of MRI activity on cognitive functions in Multiple Sclerosis G. Fenu (Cagliari, IT)

Different cognitive and pathological substrata of positive and negative emotion recognitionin subjects with multiple sclerosis

M. Pardini (Genoa, IT)

Cognitive and behavioural impact of sleep quality in newly diagnosed multiple sclerosis M.Z. Conti (Bergamo, IT)

Cognitive Theory of Mind in Multiple Sclerosis K. Zebenholzer (Vienna, AT)

Cognitive assessment should be considered in clinical trials in association with other clinicaloutcome measures

S. Ziccardi (Verona, IT)

Word List Generation test predicts conversion to disease progression in relapsing remittingmultiple sclerosis. A 6 year longitudinal study

A. Riccardi (Padua, IT)

Novelty seeking assessment and symptomatic treatment for cognitive deficits in MS M. Pardini (Genoa, IT)

Cognition in Multiple Sclerosis: An International Multidisciplinary Consensus GroupIdentifies Obstacles in the Field and Research Priorities for the Future

J.F. Sumowski (New York, US)

/ 97


Accessing early neurodegeneration in multiple sclerosis: biomarkers for diagnostics andphenotypic characterization

L. Novakova (Gothenburg, SE)

Intrathecal autologous cell therapy is associated with changes in cerebrospinal fluidbiomarkers in patients with progressive multiple sclerosis

V.K. Harris (New York, US)

Cerebrospinal fluid levels of cell-free mitochondrial DNA in patients with multiple sclerosis M. Comabella (Barcelona, ES)

Long non coding RNA expression profile in Peripheral Blood Mononuclear Cells from MultipleSclerosis patients: potential biomarkers of disease susceptibility and progression

E. Oldoni (Milan, IT)

CircularRNA profiling reveals that circularRNAs from ANXA2 could be new biomarkers formultiple sclerosis

L. Iparraguirre (San Sebastian, ES)

Metabolic imaging of hyperpolarized [1-13C] pyruvate can detected neuroinflammation inthe cuprizone model of MS

M. Chaumeil (San Francisco, US)

Altered Erythrocyte MicroRNA Profiles in Relapsing-Remitting Multiple Sclerosis K. Groen (Callaghan, AU)

Normalization of Neurofilament Light Chain Levels after Treatment with Dimethyl Fumarate T. Sejbaek (Odense, DK)

Serum exosomes microRNA-122-5p, miRNA-196b-5p, miRNA-301a-3p and miRNA-532-5prepresent a biomarkers of multiple sclerosis

I. Selmaj (Lodz, PL)

Capillary isoelectric focusing immunoassay for the detection of oligoclonal IgG- and IgMbands in cerebrospinal fluid

S. Halbgebauer (Ulm, DE)

Novel Molecular Markers Associated with Cognitive Dysfunction in Multiple Sclerosis A. Iacoangeli (New York, US)

Utility of fMRI Metrics in Assessment of RRMS Disease Progress and Severity M.P. Turner (Richardson, US)

Cerebrospilnal fluid-Actin related protein 2/3 complex subunit 4 as an astrocytic footprocess damage marker of aquaporin-4-IgG positive neuromyelitis optica spectrumdisorders

S. Nishiyama (Sendai, JP)

Biomarker for progressive multiple sclerosis: cross-sectional relationship betweendisability, multimodal evoked potentials and serum neurofilament light chain in amulticenter study

M. Hardmeier (Basel, CH)

Serum nitric oxide is increased in untreated multiple sclerosis patients F. Hallwirth (Graz, AT)

/ 97


Assessment of chitinase-3-like 1 and neurofilaments as biomarkers of cognitive function E. Quintana (Girona, ES)

Free Light Chains in cerebrospinal fluid: determination of normal values of concentration,ratio and index and their interests in a 2 years prospective study

J. Boucraut (Marseille, FR)

Cerebrospinal fluid neurofilament light chain protein is associated with radiological markersof disease activity and severity in patients with early multiple sclerosis

A. Ungureanu (Colmar, FR)

Identification of Blood Brain Barrier Permeability Mechanisms in Multiple Sclerosis: The Roleof CNS derived Endothelial Microparticles

J.R. Linden (New York, US)

Serum neurofilament light chain predicts disease activity in relapsing remitting multiplesclerosis

K. Varhaug (Bergen, NO)

Gene expression profiling study of coding and non-coding genes in peripheral bloodmononuclear cells from multiple sclerosis patients exposed to teriflunomide in vitro

S. Malhotra (Barcelona, ES)

Predicting conversion from clinically isolated syndrome to multiple sclerosis: identificationof a cerebrospinal fluid neurofilament light cut-off value

L. Gaetani (Perugia, IT)

Kappa free light chains: an automated alternative to oligoclonal bands for CIS and MSdiagnosis?

C.E. Leurs (Amsterdam, NL)

A Metabolomic study of MS patients treated with fingolimod by high resolution NMR L. Lorefice (Cagliari, IT)

Method for assessing quality of lesion volume and brain atrophy measurements Z. Spiclin (Ljubljana, SI)

Autologous haematopoietic stem cell transplantation (AHSCT) in relapse remitting (RR-MS)and secondary progressive multiple sclerosis (SP-MS): a phase II trial from St Vincent’sHospital, Sydney Australia

J. Massey (Sydney, AU)

Effectiveness of Dimethyl Fumarate on Disease Activity and Patient-Reported Outcomes inFrench Subjects with Relapsing-Remitting Multiple Sclerosis in the Real-World: A SubgroupAnalysis of PROTEC

B. Brochet (Bordeaux, FR)

First interim results of PANGAEA 2.0: Patients switching to fingolimod from other oral DMTsin daily clinical routine


The fingolimod patient profile 2011 and 2017: A comparison of two non-interventionalstudies PANGAEA and PANGAEA 2.0


/ 97


Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis T. Kalincik (Melbourne, AU)

Teriflunomide induces immunomodulatory properties by its impact on antigen-presentingcells

K. Thomas (Dresden, DE)

Interferon-beta and regulatory cells: evaluation of treatment-induced modulation of Treg,Breg and CD56bright NK cell levels in multiple sclerosis patients

S. Martire (Orbassano, IT)

Innate Immune Cell Counts in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)Treated with Cladribine Tablets 3.5 mg/kg in CLARITY and CLARITY Extension

P. Soelberg-Sorensen (Copenhagen, DK)

Infections During Periods of Grade 3 or 4 Lymphopenia in Patients Taking Cladribine Tablets3.5 mg/kg: Data from an Integrated Safety Analysis

S. Cook (Newark, US)

Proportions of Patients with Highly Active RMS Achieving No Evidence of Disease Activity(NEDA) in Response to Cladribine Tablets in CLARITY


Impact of the Presence of Gadolinium-Enhancing Lesions at Baseline on No Evidence ofDisease Activity Status in Patients Treated with Subcutaneous Interferon Beta-1a: A Post-Hoc Analysis of REFLEXION

M.S. Freedman (Ottawa, CA)

Fingolimod vs. dimethyl fumarate in relapsing-remitting multiple sclerosis: Propensity scorematched comparison in a large observational data set

J. Lorscheider (Melbourne, AU)

Immunmodulatory effects of intrathecal administration of human immunoglobulins inExperimental Autoimmune Encephalomyelitis Model in Lewis Rats

K. Pitarokoili (Bochum, DE)

Preferential reconstitution of regulatory B cell subsets following alemtuzumab treatment inMultiple sclerosis

Y. Kim (Goyang-si, KR)

Tolerogenic dendritic cells engineered to express multiple MOG epitopes using mRNAelectroporation effectively suppress MOG-specific splenocytes in vitro and in vivo

J. Derdelinckx (Edegem, BE)

Efficacy and safety of alemtuzumab in 150 patients with active relapsing-remitting MS: two-year follow-up in France

X. Ayrignac (Montpellier, FR)

Heterogeneity of peripheral blood NK cells behaviour in relapsing-remitting multiplesclerosis patients treated with dimethylfumarate

D. Marastoni (Verona, IT)

Efficacy and safety of 2 doses of ponesimod (10 and 20 mg o.d.): Interim analysis of a phaseII extension trial in relapsing-remitting multiple sclerosis

E. Havrdova (Prague, CZ)

/ 97


Transfer of Natalizumab into fetal circulation and breastmilk U. Proschmann (Dresden, DE)

Rituximab treatment in antiAQP4 positive patients with a 6-month reinfusion protocol S.L. Apóstolos-Pereira (São Paulo, BR)

Efficacy of rituximab as a rescue therapy after the failure of second line treatment inrelapsing remitting multiple sclerosis : a retrospective observational monocenter study

P. Durozard (Marseille, FR)

Safety and efficacy of rituximab in multiple sclerosis: A retrospective observational study M.M. Zeineddine (Beirut, LB)

Results of a Phase 2 trial of autologous mesenchymal cell therapy in MS (STREAMS) R. Ali (London, GB)

Cladribine personalised dosing to treat multiple sclerosis Z. Mao (London, GB)

Placebo Controlled, Phase 2a Multicenter Study of Ublituximab (UTX), a NovelGlycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms ofMultiple Sclerosis (RMS): 6 Months Analysis of B cell Subsets

A. Lovett-Racke (Columbus, US)

Real World Comparative Effectiveness data of Natalizumab vs Fingolimod for the treatmentof Relapsing-Remitting Multiple Sclerosis: Results from a Systematic Literature Review

C. Acosta (Zug, CH)

Treatment with Delayed-release Dimethyl Fumarate is Associated with Fewer Relapsesversus Glatiramer Acetate in Patients with Relapsing Remitting Multiple Sclerosis: Real-world Comparative Effectiveness Analyses from the EFFECT Study

A. Chan (Bern, CH)

The real-world efficacy of natalizumab and fingolimod in relapsing-remitting multiplesclerosis. An observational, multicentre Italian study

E. Curti (Parma, IT)

EFFICACY OF ALEMTUZUMAB IN PATIENTS WHO SWITCHED FROM FINGOLIMOD S. Eichau (Sevilla, ES)

Efficacy of Delayed-release Dimethyl Fumarate in Newly Diagnosed and Other Early MSPatients, and Patients Switching from Interferon or Glatiramer Acetate, in Routine MedicalPractice: Interim Results from ESTEEM

N.J. Everage (Cambridge, US)

Effects of Cladribine Tablets on Radiological Outcomes in High Disease Activity (HDA)Subgroups of Patients with Relapsing Multiple Sclerosis (RMS) in the CLARITY Study


PREFERMS Study: fingolimod switch effect on volumetric MRI and cognitive outcomes S.F. Hunter (Franklin, US)

Pharmacodynamics of Intravenous and Subcutaneous Doses of the Anti-CD52 AntibodyGLD52 in Patients With Progressive MS: Effects on Innate and Adaptive Immune Cells

D.H. Margolin (Cambridge, US)

/ 97


Glatiramer Acetate Depot (extended-release) Phase IIA study in patients with RelapsingRemitting Multiple Sclerosis: Six months’ interim analysis

A. Miller (Haifa, IL)

Safety, tolerability and effectiveness of dimethyl fumarate in multiple sclerosis: anindependent, multicenter, real-world study

M. Mirabella (Rome, IT)

Dimethyl fumarate reduces the frequency and function of inflammatory immune cells inrelapsing-remitting multiple sclerosis patients

G. Montes Diaz (Diepenbeek, BE)

EVOLVE-MS-1: a phase 3, open-label, long-term safety study of ALKS 8700 in relapsing-remitting multiple sclerosis

R.T. Naismith (Saint Louis, US)

Characterization of lymphopenia in Relapsing-Remitting Multiple Sclerosis patients treatedwith Dimethyl Fumarate and Fingolimod

M. Nakhaei-Nejad (Edmonton, CA)

Influence of aging and comorbidities on EDSS progression in a cohort of italian MS patients S. Ruggieri (Rome, IT)

Laquinimod induces B-cell down-regulation in primary progressive multiple sclerosis: In-vitro gene expression study

R. Zilkha-Falb (Ramat-Gan, IL)

Neuroprotective role of alemtuzumab in a chronic autoimmune mouse model with immunecell targeted deletion of BDNF

S. Demir (Bochum, DE)

Population Pharmacokinetics of Opicinumab (Anti-LINGO-1) Guides The Phase IIb DoseSelection

L.-H. Chu (Cambridge, US)

The effect of Gilenya on focal and diffuse grey matter damage in active MS patients A. Bajrami (Verona, IT)

Impact of teriflunomide on oligodendroglial homeostasis and differentiation P. Göttle (Düsseldorf, DE)

Neuroprotection in an experimental model of multiple sclerosis, via opening of bigconductance, calcium-activated potassium channels

D. Baker (London, GB)

Remyelination following oral administration of dimethyl fumarate in the Theiler’s MurineEncephalomyelitis Virus model of multiple sclerosis

N.G. Carlson (Salt Lake City, US)

VAGUS NERVE STIMULATION ATTENUATES DEMYELINATION AND ACCELERATESREMYELINATION IN A LYSOLECITHIN-INDUCED MULTIPLE SCLEROSIS MODEL

N. Hamlin (Valencia, US)

/ 97


Ozanimod (RPC1063) is potentially neuroprotective through direct activity on Th1 and Th17T cell expansion and migration, monocyte migration and microglia expansion

D. Guimond (San Diego, US)

Blockage of BMP-2 Signaling, either by Neutralizing Ab, or by Small Molecules, AmelioratesRelapsing- Experimental Autoimmune Encephalomyelitis by Induction of Neurogenesis andOligodendrogenesis

A. Karni (Tel Aviv, IL)

Ozanimod (RPC1063) is potentially neuroprotective through direct CNS effects K.R. Taylor Meadows (San Diego, US)

Recombinant human growth hormone for remyelination in MS: Results of a pilot trial inpatients with chronically delayed VEP

F. Then Bergh (Leipzig, DE)

Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis Z. Xia (Boston, US)

Long-term Effect of Fingolimod on Disability: 8-Year Disease Outcomes by EDSS Categories A.T. Reder (Chicago, US)

Real-world longitudinal data of peginterferon beta-1a from a Swedish national post-marketing surveillance study (IMSE 6) – efficacy and safety profile

S. Kågström (Stockholm, SE)

Alemtuzumab Durably Improves Clinical Outcomes in Patients With Active RRMS in theAbsence of Continuous Treatment: 7-Year Follow-up of CARE-MS-I Patients (TOPAZ Study)

A.J. Coles (Cambridge, GB)

Durable Reduction in MRI Disease Activity and Slowing of Brain Volume Loss WithAlemtuzumab in Patients With Active RRMS: 7-Year Follow-up of CARE-MS I Patients (TOPAZStudy)

D.L. Arnold (Montréal, CA)

Alemtuzumab Demonstrated Durable Efficacy and Safety in CARE-MS I Patients SwitchingFrom SC IFNB-1a: 5-Year Follow-up After Alemtuzumab (TOPAZ Study)

C. Oreja-Guevara (Madrid, ES)

Baseline Characteristics and Long-term Disability Outcomes: Subgroup Analysis of theTEMSO and TOWER Core and Extension Studies

P. Vermersch (Lille, FR)

5 years safety experience with fingolimod in real world: Results from PANGAEA, a non-interventional study of RRMS patients treated in Germany


Persistence to fingolimod compared with other disease modifying therapies in theAustralian Real-World setting using the MS Base registry


Alemtuzumab Efficacy and Safety Were Durable Over 5 Years After Switching From SCIFNB-1a: Follow-up of Patients From CARE-MS II (TOPAZ Study)

B. Van Wijmeersch (Hasselt, BE)

/ 97


Alemtuzumab-Treated Patients With Relapsing-Remitting MS Show Low Rates of Conversionto Secondary Progressive MS: 6-Year Follow-up of CARE-MS I and II

D. Horáková (Prague, CZ)

Early versus late treatment start in patients with multiple sclerosis - A nationwide register-based study

T.A. Chalmer (Copenhagen, DK)

Long-term effect of interferon-β use in real-world settings on disability progression: Aseries of 2,451 relapsing-remitting multiple sclerosis patients, Rennes, France

M. Lefort (Rennes, FR)

Patient-Reported Disability in Patients with Multiple Sclerosis on Baseline Therapy: Resultsfrom the Non-Interventional PEARL Study over 2 years

R. Haase (Dresden, DE)

Real-time monitoring of MS-immunotherapy discontinuation, switching, and restarting witha Visualisation and Analysis Platform (VAP) implemented in the Swedish MS-Registry

L. Stawiarz (Stockholm, SE)

A Swedish Nationwide Pharmaco-Epidemiological Study of the Long-Term Safety andEffectiveness of Teriflunomid (IMSE 4)

L. Forsberg (Stockholm, SE)

Long term extended interval dosing of Natalizumab does not change its clinico-radiologicalefficacy nor saturation capacity of CD49d: a real life study in a French MS center

D. Ciocanu (Caen, FR)

Effect of comorbidities on dimethyl fumarate persistence and effectiveness in patients withrelapsing remitting multiple sclerosis in a real world clinic setting

T.L. Campbell (Halifax, CA)

Long-term Disability Outcomes in Patients Treated With Teriflunomide for up to 14 Years:Group- and Patient-Level Data from the Phase 2 Extension Study

M.S. Freedman (Ottawa, CA)

Long-term Improvement in Clinical Outcomes in Alemtuzumab-Treated RRMS Patients WhoRelapsed Between Courses 1 and 2 (CARE-MS I)

H. Wiendl (Münster, DE)

Identifying Barriers to Effective Communication Between Individuals with MS andHealthcare Professionals: A Global Survey of MS Healthcare Professionals

A. Montague (Cherry Hill, US)

Early diagnosis of PML: results from the Italian cohort C. Scarpazza (Brescia, IT)

A case of fulminant Goodpasture syndrome following alemtuzumab treatment for multiplesclerosis

E. Lapointe (Vancouver, CA)

Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient afteralemtuzumab treatment

S. Barone (Catanzaro, IT)

/ 97


Recurrent immune thrombocytopenic purpura secondary to rituximab administered asneuromyelitis optica treatment. A case report presentation

J. Meca-Lallana (Murcia, ES)

Higher Medication Satisfaction and Treatment Adherence in Relapsing-Remitting MultipleSclerosis Patients Treated With Glatiramer Acetate 40 mg/mL Three-Times WeeklyCompared With 20 mg/mL Daily: 6-Month Results of the CONFIDENCE Study

A. Veneziano (Frazer, US)

Design and implementation of an automated platform supporting the Alemtuzumab riskmanagement plan: The Alemtuzumab MS Safety Systems (AMS3) study

S. Reddel (Sydney, AU)

ABO blood groups and secretion status is associated with JC polyomavirus antibody levels inplasma: a genome-wide association study

T. Olsson (Stockholm, SE)

Effectiveness and Safety of Fingolimod in Patients with Multiple Sclerosis Switched fromNatalizumab: Results from TRANSITION − a 2-year Observational Study


Which total lymphocyte count may predict a low number of CD4 T cells under dimethylfumarate ?

J. Boucher (Lille, FR)

Severe Reactivation of Multiple Sclerosis following withdrawal of Fingolimod: a case seriesGaughan M, Costelloe L Department of Neurology, Beaumont Hospital

M. Gaughan (Dublin, IE)

Stability of a Negative JCV Test E. Williamson (Philadelphia, US)

Reductions in immunoglobulin levels following natalizumab-to-rituximab crossover in amultiple sclerosis cohort: implications for next generation B cell-targeted therapies

M.M. Foley (Salt Lake City, US)

Switching from natalizumab to alemtuzumab: A Case series N.A. John (London, GB)

Comparison of Reproductive and Juvenile Nonclinical Findings Between Ozanimod andFingolimod

S. Meier-Davis (San Diego, US)

Lateral ventricular volume measurement is feasible on low-resolution T2-FLAIR MRI inpediatric MS

M.G. Dwyer (Buffalo, US)

Impact of fingolimod on MRI brain volume measures in RRMS patients with active disease atbaseline: results from MS-MRIUS, a longitudinal observational, multicenter real-worldoutcome study in a clinical routine


Early biomarkers of response in Multiple sclerosis patients treated with natalizumab:clinical, genetic and environmental


/ 97


Prediction of Treatment Response in alemtuzumab treated RRMS patients by distinctimmune phenotypes and deep immune sequencing

T. Ruck (Münster, DE)

MIMoSA: A Method for Inter-Modal Segmentation Analysis of T2 Hyperintensities and T1Black Holes in Multiple Sclerosis

A. Valcarcel (Philadelphia, US)

Differential effect on lymphocyte subsets and transcriptome sequencing after treatmentwith fingolimod in relapsing-remitting multiple sclerosis patients. Prognostic implications

I. Moreno Torres (Majadahonda, ES)

Interim analysis from FLOODLIGHT: a prospective pilot study to evaluate the feasibility ofconducting remote patient monitoring with the use of digital technology in patients withmultiple sclerosis

P. Mulero (Barcelona, ES)

Establishing pathological cut-offs for lateral ventricular volume expansion rates M.G. Dwyer (Buffalo, US)

Predicting disease activity and disability progression in RRMS patients on natalizumab I. Dekker (Amsterdam, NL)

The role of geographic location as a treatment effect modifier in multiple sclerosis E. Sgarlata (Rome, IT)

Fampridine improves horizontal eye movements in patients with multiple sclerosis andinternuclear ophthalmoplegia: a double-blind, placebo-controlled crossover study

K.M.S. Kanhai (Leiden, NL)

Abrogation of the lymphocyte depleting action of Alemtuzumab by neutralizing antibodies –a case report

C. Eggers (Linz, AT)

Effect of Fingolimod 0.5 mg/day vs Placebo on Two Newly Developed Expanded DisabilityStatus Scale (EDSS) Subscales for Relapsing-remitting MS Patients: EDSS Factor Analysis

G. Cutter (Birmingham, US)

MRI diffusion metrics are sensitive to changes due to fingolimod treatment Q. Yu (Brisbane, AU)

Sustained and durable reduction in confirmed disability progression in patients withprimary progressive multiple sclerosis receiving ocrelizumab: findings from the phase IIIORATORIO study extended control period

J.S. Wolinsky (Houston, US)

Enhancing brain plasticity to contrast clinical progression in MS: a pilot study assessing thesafety and efficacy of D-Aspartate

C.G. Nicoletti (Rome, IT)

Effect of ocrelizumab on upper limb function in patients with primary progressive multiplesclerosis in the ORATORIO study

E.J. Fox (Round Rock, US)

/ 97


Disease-modifying therapies use in primary progressive multiple sclerosis patients inFrance: data from the OFSEP cohort over the 1996-2017 period

E. Leray (Rennes, FR)

Longitudinal changes in lymphocyte subsets of siponimod-treated patients with SPMS A. Bar-Or (Philadelphia, US)

Impact of Primary Endpoint Definitions and Patient Baseline Characteristics on StudyOutcomes in Progressive Multiple Sclerosis

R. Gold (Bochum, DE)

Fingolimod treatment increase peroxisome proliferator-activated receptor (PPAR) γ andCD36 receptor gene expression in blood leukocytes of multiple sclerosis patients

C. Capela (Lisboa, PT)

Neurologists’ Understanding of Advances in Multiple Sclerosis (MS) Across Europe, SouthAmerica, and the United States

G. Comi (Milan, IT)

Recombinant protein analogous to human sIFNAR2 as a potential new drug for MultipleSclerosis

B. Oliver-Martos (Málaga, ES)

Disease Modifying Therapies: trending choices and the what’s and why’s to switching D. Lux (Canterbury, GB)

Calorie restriction diets and changes in the metabolome in people with multiple sclerosis K.C. Fitzgerald (Baltimore, US)

Real-World Assessment of Relapse in Patients With Multiple Sclerosis Newly InitiatingscIFNβ1a Compared With Oral Disease-Modifying Drugs

J. Bowen (Seattle, US)

Cardiorespiratory fitness and cardiovascular autonomic control in patients with mild tomoderate relapsing remitting Multiple sclerosis following 6 week endurance exerciseprogram

M. Abolhasani (Tehran, IR)

A Risk Aversion Calculator for Augmenting the Disease Modifier Selection Process L. Hartsell (Durham, US)

Disease activity following pregnancy-related discontinuation of natalizumab in multiplesclerosis

I. Kleerekooper (Amsterdam, NL)

A post-marketing observational monocentric study of efficacy and tolerability ofDimetilfumarate


Evaluation of postural balance in women with multiple sclerosis in different sensoryconditions using force platform

A.G. Moraes (Brasília, BR)

/ 97


An Evaluation of Adherence Using Panel Survey Data From Patients With Multiple SclerosisTreated With Subcutaneous Interferon β-1a or Dimethyl Fumarate

A. Perrin Ross (Maywood, US)

Treatment patterns of relapsing remitting multiple sclerosis (RRMS) in Europe and theUnited States


Physician and patient treatment decision-making in relapsing-remitting multiple sclerosis inEurope and the United States


Switching to natalizumab is associated with improvements in cognitive function asmeasured by NeuroTrax


Acupuncture for patients with multiple sclerosis associated fatigue – a randomizedcontrolled trial

J. Bellmann-Strobl (Berlin, DE)

Evidenced Based Cognitive Rehabilitation for Persons with Multiple Sclerosis: An UpdatedReview of the Literature from 2007-2016

Y. Goverover (New York, US)

The Adult Spasticity International Registry (ASPIRE) Study: Treatment Utilization Patternsin Patients with Multiple Sclerosis Patients Treated for Spasticity

D. Bandari (Newport Beach, US)

A Pilot Randomized Controlled Trial Evaluating the Effects of a Resilience Intervention onAdults Aging with Multiple Sclerosis

D.M. Ehde (Seattle, US)

Effects of a maximum strength training program on perceived fatigue and functional abilityin patients with multiple sclerosis

R. Gomez-Illan (Elche, ES)

Is the effect of personalized multidisciplinary rehabilitation on physical function dependenton multiple sclerosis phenotype? – Part of the Danish MS Hospitals Rehabilitation Study

L.G. Hvid (Aarhus, DK)

Magnitude of Response to Dalfampridine Correlates with Diffusion Tensor Imaging Metrics S. Klineova (New York, US)

Effects of normobaric hypoxic training on physical fitness and immunoregulatory functionsin patients with multiple sclerosis: a pilot study

A. Mähler (Berlin, DE)

Effect of videogame-based physical activity training in persons with multiple sclerosis: arandomised controlled trial

A.T. Ozdogar (Izmir, TR)

Natalizumab is associated with stable or improved cognitive function, health-related qualityof life, and work capacity in anti–JC virus seronegative patients with early relapsing-remitting multiple sclerosis: a 2-year analysis of STRIVE

J. Perumal (New York, US)

/ 97


Everyday technology use in MS: Limitations and opportunities in using everyday technologyin persons with MS

Y. Goverover (New York, US)

Qualitative factors on initiation, satisfaction and adherence to aquatic exercise in thecommunity among persons with multiple sclerosis

C. Santoyo (Barcelona, ES)

Understanding Patient Underreporting of MS Relapses: Insights from Patients with MultipleSclerosis from the Harris Poll 2017 Survey

E.N. Banfe (Hampton, US)

Increased adherence and better satisfaction outcomes with oral treatments in Relapsing-Remitting Multiple Sclerosis patients

I. González-Suárez (Madrid, ES)

Employment Status and Health-Related Quality of Life of MS patients in a never treated andonly ever treated with IFNβ-1a sc cohorts: An exploratory study

S. Hum (Montreal, CA)

The association between energy cost of walking and leisure-time physical activity in peoplewith multiple sclerosis

A. Kalron (Herzeliya, IL)

Evaluation of a web-based fall prevention program among people with multiple sclerosis M. Kannan (Portland, US)

Expanding Our Understanding Of Daily Life Activity Impact In Patients With MultipleSclerosis

J. Petrillo (Cambridge, US)

Multicenter Open-label non-interventional study assessing the alteration of activity inambulatory patients with relapsing forms of MS (RMS) under treatment with COPAXONE®40 mg tiw - Results of an interim analysis of the NIS COPTIVITY


Social Media Session, Hall D15:45 - 16:45 Google Hangout

A google hangout broadcast from ECTRIMS with Barts MS researchers with peoplewith MS sharing highlights from the meeting.

ChairsA. Thomson (London, GB)M. Marta (London, GB)

15:45 - 16:15 Presentation 1 D. Baker (London, GB)

16:15 - 16:45 Presentation 2 S. Gnanapavan (London, GB)

/ 97


Hot Topic Sessions, Hall A17:00 - 17:45 Hot Topic 7: Controversy 2: Anti-MOG disease: a new

entity different from NMO spectrum disorder?

ChairsJ. de Seze (Strasbourg, FR)A. Traboulsee (Vancouver, CA)

17:00 - 17:15 For D.K. Sato (Porto Alegre, BR)

17:15 - 17:30 Against R. Marignier (Lyon, FR)

17:30 - 17:35 Summary A. Traboulsee (Vancouver, CA)

17:35 - 17:45 Disease course and disability outcomes in MOG-antibody disease in theUK

M. Jurynczyk (Oxford, GB)

Hot Topic Sessions, Hall B17:00 - 17:45 Hot Topic 8: Aging with MS

ChairsT. Moreau (Dijon, FR)M. Tintoré (Barcelona, ES)

17:00 - 17:15 CIS: prognosis after 30 years D. Chard (London, GB)

17:15 - 17:30 Role of comorbidities in aging MS patients R.A. Marrie (Winnipeg, CA)

17:30 - 17:45 Disease modifying therapy in the aging MS patient J. Corboy (Aurora, US)

Hot Topic Sessions, Hall C17:00 - 17:45 Hot Topic 9: Immune cells on the move

ChairsM. Kerschensteiner (Munich, DE)R. Liblau (Toulouse, FR)

17:00 - 17:15 Revisiting immune privilege of the CNS/ the role of a functionalmeningeal lymphatic system

J. Kipnis (Rehovot, US)

/ 97


17:15 - 17:30 The role of B cells and antibodies on both sides of the blood brain barrierin MS

M. Weber (Goettingen, DE)

17:30 - 17:45 B cells from bench to bedside in MS B. Hemmer (Munich, DE)

Hot Topic Sessions, Hall D17:00 - 17:45 Hot Topic 10: Insight from new imaging methods

ChairsB. Stankoff (Paris, FR)O. Ciccarelli (London, GB)

17:00 - 17:15 New insights in brain microstructure and metabolism using advanced MRI J.-P. Ranjeva (Marseille, FR)

17:15 - 17:30 Assessing lesion dynamics in the brain and spinal cord by High field MRI D. Reich (Bethesda, US)

17:30 - 17:45 OCT and the course of MS F. Costello (Calgary, CA)


Supported by Roche


Supported by Novartis

/ 97


Saturday, 28 October 2017

Satellite Symposia, Hall A07:45 - 08:15 Mini Satellite Symposium

Supported by MedImmune

Parallel Sessions, Hall A08:30 - 10:00 Parallel Session 16: Late Breaking News

ChairsJ. Antel (Montreal, CA)R. Hohlfeld (Munich, DE)

Plenary Sessions, Hall A10:30 - 12:30 Plenary Session 2: Charcot lecture ECTRIMS Highlights &

Awards & ECTRIMS Honorary Members

10:30 - 11:10 Presentation of selected ECTRIMS poster awards, awards for bestECTRIMS oral presentations by young researchers, the MSIF award aswell announcement of ECTRIMS Honorary Members

11:10 - 11:40 Charcot Lecture

11:40 - 12:00 Clinical highlights R.J. Fox (Cleveland, US) A.J. Coles (Cambridge, GB)

12:00 - 12:20 Scientific highlights D. Laplaud (Nantes Cédex, FR) A. Green (San Francisco, US)

12:20 - 12:25 Welcome to Berlin R. Hohlfeld (Munich, DE)

Powered by TCPDF (www.tcpdf.org)

/ 97

http://www.tcpdf.org

Programme Ectrims 2017

Health & Medicine

Transcript of Programme Ectrims 2017